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I. Cohort Descriptions 
East Asian Exome Chip Cohorts 
Chinese Eye Study (CHES) 
CHES study is a 5-year, population-based study recruited 4570 non-institutionalized Chinese Americans, aged 50 years and older, in the city of 
Monterey Park in Los Angeles County, and to determine risk indicators associated with these ocular diseases
1
. 
 
China Health and Nutrition Survey (CHNS) 
CHNS was designed to understand how the wide-ranging social and economic changes in China affect a wide array of nutrition and health-related 
outcomes. Since 1989, CHNS has collected longitudinal anthropometry, blood pressure, diet and lifestyle data on ~4,400 households with a total 
of ~26,000 individuals in nine Chinese provinces that vary substantially in geography, economic development and health indicators. In the 2009 
survey, the CHNS collected blood from which major cardiovascular and nutrition biomarkers were measured and DNA was extracted. Genome-
wide genotyping were carried out in a subset of 8,405 individuals
2
. All blood samples were processed in a national central lab in Beijing. HDL-C 
and LDL-C were measured via homogeneous enzymatic methods, TG was measured using GPO-PAP method, and TC were measured by CHOD-
PAP method. 
 
Cebu Longitudinal Health and Nutrition Survey(CLHNS) 
CLHNS is an ongoing community-based birth cohort study that began in 1983. The baseline survey randomly recruited 3,327 pregnant women 
from the Metropolitan Cebu area, the Philippines in 1983-84 (3,080 singleton live births), and since followed them and their offspring to the 
present
3
. Trained field staff conducted in-home interviews and collected anthropometric measurements at each visit. Blood samples for biomarker 
measurement and DNA extraction were obtained in 2005. For this study of 1,779 CLHNS mothers, weight, height, and the calculated BMI were 
ascertained in the 2005 survey. 
 
Fangchenggang Area Male Health and Examination Survey(FAMHES) 
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All samples in this study were collected from the Fangchenggang Area Male Health and Examination Survey (FAMHES)
4
, which was mainly 
focused on environmental and genetic factors, as well as their interrelations. In the comprehensive demographic and health survey, 4303 men 
participated in routine physical examination at the Medical Centre in Fangchenggang First People’s Hospital from September to December 2009. 
As a population-based study conducted among non-institutionalized Chinese men aged from 18 to 88 years old in Guangxi, FAMHES investigated 
the development of age-related chronic disease.  
 
Guizhou-Bijie Type 2 Diabetes Study (GBTDS) 
GBTDS is a population-based case-control study conducted from September 2009 to January 2010 in Bijie city of Guizhou province
5
. The 
participants include 1,824 type 2 diabetic cases (955 male and 869 female) and 1,719 nondiabetic controls (828 male and 891 female) aged 30 to 
80 years, with at least 10 years residence in Bijie city. All participants are unrelated Chinese Hans and recruited through advertisement. The 
participants were asked to attend a complete physical examination in the Bijie People’s Hospital to collect standard anthropometric measurements 
and blood samples, and to complete a comprehensive questionnaire to collect information on demographic variables, health status, health behavior, 
and physical activity. Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides 
were enzymatically measured in fasting blood samples by an automatic analyzer (Hitachi 7080, Japan). For the current study, 846 T2D cases and 
829 controls were genotyped using exome array. After quality control, 837 T2D cases and 815 controls were included in the analysis. 
 
The University of Hong Kong Theme-based Research Scheme (HKU-TRS)    
HKU-TRS is a collaborative study aiming to identify genetic factors contributing to cardiovascular disease
6
. We genotyped 6,048 Southern 
Chinese subjects recruited from the Chinese CAD Cohort of the Queen Mary Hospital in Hong Kong; Hong Kong Cardiovascular Risk Factor 
Prevalence Study (CRISPS) and Hong Kong West Diabetes Registry (HKWDR). Fasting blood samples were collected and plasma lipids were 
measured by standard enzymatic methods. LDL-C level was calculated using the Friedewald equation or by direct enzymatic colorimetric test if 
TG was >4.5 mmol/L. For the quantitative blood lipids analyses, we included 5,233 subjects (2,372 CAD cases and 3,388 non-CAD controls) who 
were not taking any lipid-lowering drug or those with their pre-treatment lipid levels available. 
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Hubei Coronary Artery Disease study (HuCAD) 
The HuCAD initially included a total of 5111 CAD patients and 5002 age (±5 years) and gender (matched on frequency) matched controls 
recruited in Hubei, Wuhan, China. CAD patients were recruited consecutively from 3 hospitals in Wuhan, Hubei, China (Tongji Hospital, Union 
Hospital and Wugang Hospital) between 2004 and 2012
7
and Dongfeng Central Hospital in Shiyan, Hubei, China between 2008 and 2012 (most of 
these patients have been registered into Dongfeng–Tongji cohort8). The diagnostic criteria for CAD cases included having a documented history 
ofcoronary artery bypass graft or percutaneous coronary intervention, the presence ofa stenosis ≥50% in at least 1 of the major segments of 
coronary arteries on coronary angiography, and/or a diagnosis of CAD based on the World Health Organization criteria. Controls were selected 
from the DFTJ cohort(Wang F et al., Int J Epidemiol, 2013), the Wuhan-Zhuhai cohort (Song Y et al., BMC Public Health, 2014) and the Wuhan 
cohort of coke oven workers(Li X et al., PLoS One, 2012). All controls were free of ischemic heart disease, stroke, diabetes and cancer by the time 
when the study was conducted. Of the initially genotyped 10113 individuals, 4664 CAD cases and 4533 controls passed quality control criteria, 
among which 4327 cases and 4187 controls available for complete lipid traits were eligible for the present analysis. Blood specimens were 
obtained after participants had fasted overnight (≥8 h). The plasma TC, TG, LDL-C and HDL-C levels were measured by the ARCHITECT 
Ci8200 automatic analyzer (ABBOTT Laboratories. Abbott Park, Illinois, USA) using the Abbott Diagnostics reagents according to the 
manufacturer’s instructions in each hospital or examination center. 
  
The Nutrition and Health of Aging Population in China (NHAPC)  
The NHAPC is a population-based study among non-institutionalized Chinese people aged 50 to 70 years in Beijing and Shanghai, which was 
designed to investigate the effects of environmental and genetic factors and their interaction on the development of age-related chronic diseases
9
. 
The study design, methods and measurements of this cohort study have been described in detail elsewhere. Briefly, the participants were recruited 
using a multistage sampling method from 2 urban districts and 1 rural district of each city. Data on demographic variables, health status, health 
behavior, and physical activity was collected using a standardized questionnaire, and standard anthropometric measurements and overnight fasting 
blood samples were collected using a standardized protocol when the participants attended a physical examination. A total of 3,289 eligible 
participants (1,458 men and 1,831 women) were recruited. For this study, the exome-wide association study was conducted among 3,161 
individuals. After stringent quality control, 1,999 subjects were included in the analysis. Peripheral venous ethylenediaminetetraacetic acid blood 
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samples were collected and centrifuged at 4°C, 3,000 rpm for 15 min. After being frozen, the samples were shipped in dry ice to the Institute for 
Nutritional Sciences and stored at −80°C until analysis. Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, and triglycerides were enzymatically measured on an automatic analyzer (Hitachi 7080, Japan) with reagents purchased from 
Wako Pure Chemical Industries (Osaka, Japan). 
 
Peking University Health Science Center and the University of Michigan Medical School study of Myocardial Infarction (PUUMA.Capital) 
Samples from China were collected by the Joint Institute of the Peking University Health Science Center and the University of Michigan Medical 
School study of Myocardial Infarction (PUUMA-MI)
6
.  PUUMA-MI is a large-scale project designed to study cardiovascular disease and related 
traits including myocardial infarction (MI) and plasma lipid levels. Fasting plasma lipid levels (including serum total cholesterols, LDL cholesterol, 
HDL cholesterol and triglycerides) were tested using Roche cobas 8000 modular analyzer series (Indianapolis , IN, USA)  in Beijing Shijingshan 
cohort samples (N=836) and Beckman coulter UniCelDxC 800 Synchron (Brea, CA, USA ) in Peking University First Hospital-based samples 
(N=7,339) after overnight fasting, respectively. 
 
Peking University Health Science Center and the University of Michigan Medical School study of Myocardial Infarction (PUUMA.Case, 
PUUMA.Control) 
Samples from China were collected by the Joint Institute of the Peking University Health Science Center and the University of Michigan Medical 
School study of Myocardial Infarction (PUUMA-MI)
6
.  PUUMA-MI is a large-scale project designed to study cardiovascular disease and related 
traits including myocardial infarction (MI) and plasma lipid levels. Blood samples were taken in the morning after an overnight fast and collected 
into vacuum tubes containing EDTA for the measurement of plasma lipids. Clinical chemical analyses were conducted at the central chemistry lab 
of Peking University Third Hospital. Using Beckman Coulter AU 5800 Auto-Analyzer (Tokyo, Japan), total cholesterol was measured by an 
enzymatic method (Baiding Biological Engineering Ltd., Beijing, China); triglycerides were measured by an enzymatic (with peroxidase) method 
(Biosino Bio-Technology Co., Ltd., Beijing, China); and high density lipoprotein cholesterol and low density lipoprotein cholesterol were 
measured by a liquid selective detergent method (Sekisui Medical Co., Ltd., Tokyo, Japan). The day-to-day coefficients of variation were 0.9%-
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2.0% for total cholesterol, 1.6% for high density lipoprotein-cholesterol, 1.5% for low density lipoprotein-cholesterol and 0.8% - 2.1% for 
triglyceride. 
 
Shanghai breast cancer study(SBCS)   
The SBCS is a population-based, case-control study conducted in urban Shanghai
10
. Subject recruitment in the initial phase of the SBCS (SBCS-I) 
was conducted between August 1996 and March 1998. The second phase (SBCS-II) of recruitment occurred between April 2002 and February 
2005. Controls were randomly selected using the Shanghai Resident Registry.  Only controls were included in this study. 
 
Singapore Chinese Eye Study (SCES)    
The SCES is the Chinese equivalent to SiMES, where the sampling was similarly performed in the same 15 residential districts and included 3,353 
Singaporean Chinese subjects
11
. Non-fasting venous blood was collected for SiMES subjects and serum blood lipids using enzymatic methods 
implemented in the Advia 2400 Chemistry System (Siemens Medical Solutions Diagnostics, Deerfield, IL). In total 2,461 Singaporean Chinese 
adult subjects from SCES were genotyped on the Illumina HumanExomeBeadchip. Sample QC measures excluded 1 subjects with low call-rates 
(<99%), 66 subjects with low heterozygozity (< Median + 3*IQR), 39 1st degree related individuals and 9 PCA outliers and 2,461 SCES Chinese 
adult samples were available for subsequent statistical analysis. 
 
Singapore Malay Eye Study (SiMES)    
The SiMESis a population-based and cross-sectional study which aimed to investigate the epidemiology of eye diseases in Singapore Malays aged 
40-80
12
. Initially, resident adults were selected through an age-stratified random sampling from the 15 residential districts in South-western 
Singapore to obtain approximately equal numbers in each decade between the ages 40-80. 3280 Malay adults were eligible and participated in the 
study. Non-fasting venous blood was collected for SiMES subjects and serum blood lipids using enzymatic methods implemented in the Advia 
2400 Chemistry System (Siemens Medical Solutions Diagnostics, Deerfield, IL). A total of 2,469 SiMES Singaporean Malay subjects were 
genotyped on the Illumina HumanExomeBeadchip. Sample QC measures excluded 11 subjects with low call-rates (<99%), 7 subjects with low 
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heterozygozity(< Median + 3*IQR), 4 1st degree related individuals and 2 PCA outliers and 2,445 SiMES Malay subjects were available for 
subsequent statistical analysis. 
 
Shanghai Men's Health Study(SMHS)    
The SMHS is a population-based cohort study of 61,480 Chinese men between ages 40 and 74 who lived in 8 urban communities in Shanghai at 
enrollment (2002-2006)
13
. Detailed information on dietary and other lifestyle factors was collected at baseline and is being updated in follow-up 
surveys. Biological samples (blood, and or urine) were collected from 89% of cohort members. The cohort has been followed up for cancer 
occurrence and deaths.  
 
Singapore Prospective Study Program (SP2)    
The SP2 is a population-based study of diabetes and cardiovascular disease in Singapore that has been described previously
12
. The SP2 has 
recruited 10,633 Chinese, Malay, and Indian subjects from four cross-sectional studies that were conducted in Singapore between 1984 and 1998. 
Subjects were aged 18-69 at baseline and represented a random sample of the Singapore population, with over-sampling of the minority Malay and 
Indian ethnic groups to achieve a ratio of 60:20:20 in the overall sample. From 2003 to 2007, 7,772 subjects were re-contacted and interviewed, 
5,094 of whom provided fasting blood samples, after a 10 hour overnight fast, and other clinical data. Serum lipids were measured using kits from 
Boehringer Mannheim Systems (Mannheim, Germany) and read on a BM/Hitachi 747 analyzer (Roche Diagnostics, Corp. Indianapolis, IN). In 
total 961 Singaporean Chinese adult subjects were genotyped on the Illumina HumanExomeBeadchip. Sample QC measures excluded 9 subjects 
with low call-rates (<99%), 11 1st degree related individuals and 4 PCA outliers and 936 SP2 Chinese adult samples were available for subsequent 
statistical analysis.  
 
Shanghai Women's Health Study(SWHS)    
The Shanghai Women's Health Study (SWHS) is a large population-based prospective cohort study initiated in 1996
14
. Approximately 75,000 
Chinese women who lived in Shanghai were recruited into the study. In addition to survey data, blood and urine samples were collected from most 
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study participants at the baseline recruitment. This cohort of women has been followed for cause-specific mortality and site-specific cancer 
incidence. 
 
Taiwan USA Diabetes Retinopathy(TUDR)    
TUDR study is a cohort that enrolled subjects with T2DM receiving care at Taichung Veterans General Hospital, Taichung, Taiwan, and a small 
number of subjects were included from Tri-Service General Hospital, Taipei, Taiwan.  All TUDR subjects underwent a complete fundoscopic 
examination to carefully document the presence and extent of retinopathy
15
. 
 
Chinese GWAS Cohorts 
The Beijing Atherosclerosis Study (BAS)  
The BAS consisted of 505 cases of MI and 1,021 controls
16-17
. All participants were from Beijing, China. All cases had a validated history of MI 
and were verified by hospital records and by cardiologists according to standard protocol. Controls were randomly selected from subjects 
participating in a community based survey of cardiovascular risk factors in Beijing. The control subjects were judged to be free of CAD by history, 
clinical examination, electrocardiography, and Rose questionnaire. Detailed data were collected through in-person interviews with each case and 
control. Subjects with congenital heart disease, cardiomyopathy, valvular disease, and renal or hepatic disease were excluded. Overnight fasting 
blood samples were drawn by venipuncture to measure lipid levels. Blood specimens were processed in the central clinical laboratory at the 
Department of Population Genetics at Fuwai Hospital of the Chinese Academy of Medical Sciences in Beijing. This laboratory participates in the 
Lipid Standardization Program of the US Centers for Disease Control and Prevention and National Heart, Lung, and Blood Institute. Study 
obtained approval from institutional review boards of Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
and other medical institutions, and all participants gave written informed consents. 
 
The China Atherosclerosis Study (CAS)  
The CAS consisted of 1,010 cases of CAD and 3,998 controls
16-17
. 1,010 cases from the Northern provinces in China were enrolled from Fuwai 
Hospital, National Center For Cardiovascular Diseases. 83.8% of cases have a family history of CAD. Controls of CAS study were recruited from 
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the International Collaborative Study of Cardiovascular Disease in Asia (InterASIA in China). InterASIA used a four-stage stratified sampling 
method to select a nationally representative sample of the general population aged 35 to 74 years in China. 3,998 controls were individuals who 
did not develop incident CAD and had no family history of CAD during the 8 yr follow-up period of the study from four northern field centers of 
InterASIA. Overnight fasting blood samples were drawn by venipuncture to measure lipid levels. Blood specimens were processed in the central 
clinical laboratory at the Department of Population Genetics at Fuwai Hospital of the Chinese Academy of Medical Sciences in Beijing.Study 
obtained approval from institutional review boards of Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
and other medical institutions, and all participants gave written informed consents. 
 
 
GLGC Exome Chip Cohorts: 
British 1958 Birth Cohort (1958BC) 
The National Child Development Study (NCDS) follows the lives of 17,000 people born in England, Scotland and Wales in a single week of 
1958
18
. Also known as the 1958 Birth Cohort Study, it collects information on physical and educational development, economic circumstances, 
employment, family life, health behaviour, wellbeing, social participation and attitudes. The NCDS is managed by CLS and funded by the 
Economic and Social Research Council. Since the birth survey in 1958, there have been nine further ‘sweeps’ of all cohort members at ages 7, 11, 
16, 23, 33, 42, 46, 50 and 55. In 2003 (at age 45), 9,000 cohort members also participated in a special bio-medical survey so we could learn more 
about how development, environments and lifestyles affect people’s health. 
 
Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care - Denmark screening cohort 
(ADDITION) 
The Danish ADDITION Study (Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care) is a 
high-risk screening and intervention study for type 2 diabetes in general practice sampled by Department of General Practice at University of 
Aarhus, Denmark (ClinicalTrials.gov ID-no: NCT00237548)
19
. The 8,662 participants from the initial screening cohort with available DNA 
included 1,626 participants with screen-detected and untreated T2D and 7,036 non-diabetic subjects. Patients with T2D were diagnosed by two 
independent diabetic values at baseline investigation or at one-year follow-up. Phenotypes include anthropometrics, basal fasting biochemistry (e.g. 
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plasma glucose, serum insulin, HbA1C and lipids) and health and lifestyle questionnaires. Here 2238 participants from the Danish screening 
cohort with information on lipids and exome chip were analyzed. 
 
Age gene/environment susceptibility Reykjavik study (AGES) 
The AGES study has been described previously
20
. The study was initiated in 2002 to examine genetic susceptibility and gene/environment 
interactions related to disease and disability in old age. The AGES study is comprised of 5764 individuals drawn from the Reykjavik Study, a 
population-based cohort comprised of individuals born between 1907 and 1935 and followed since 1967 by the Icelandic Heart Association. 3219 
individuals chosen randomly among 5307 AGES individuals with ‘mid-life’ data available from the Reykjavik Study were genotyped on a 
genome-wide association (GWA) array. 2983 individuals randomly selected from the 3219 individuals with GWA were further genotyped for the 
ExomeChip. 
 
Academic Medical Center Premature Atherosclerosis Study (AMCPAS) 
Cases were recruited as part of a prospective cohort study (Academic Medical Centre Amsterdam Premature Atherosclerosis Study (AMC-PAS) 
with symptomatic CAD before the age of 51 years, defined as MI, coronary revascularization, or evidence of at least 70% stenosis in a major 
epicardial artery
21
. 
 
Atherosclerosis Risk in Communities Study (ARIC-AA, ARIC-EA) 
The ARIC study has been described in detail previously
22
. Men and women aged 45-64 years at baseline were recruited from four communities: 
Forsyth County, North Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County, Maryland. A total of 15,792 individuals, 
predominantly White (EA) and African American (AA), participated in the baseline examination in 1987-1989, with three additional triennial 
follow-up examinations and a fifth exam in 2011-2013. 
 
Anglo-Scandinavian Cardiac Outcome Trial [Scandinavians] (ASCOT-SC) 
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ASCOT is a randomised control clinical trial investigating the cardiac outcomes of blood pressure lowering and lipid lowering treatments
23
. Of 
19,342 hypertensive patients (40–79 years of age with at least three other cardiovascular risk factors) who were randomized to one of two 
antihypertensive regimens in ASCOT, 10,305 with non-fasting TC concentrations of 6.5 mmol/l or less (measured at the non-fasting screening 
visit) had been randomly assigned additional atorvastatin 10 mg or placebo. These patients formed the lipid-lowering arm of the study. Only a 
proportion of United Kingdom, Irish, Sweden, Norway, Finland and Denmark consented to contribute DNA and participate in genetic studies. 
Blood lipid levels used in this analysis were measured at the (fasting) randomization visit and LDL- C was estimated using the Friedewald 
equation. The ASCOT-SC sample analysed here is restricted to the patients from Scandinavia, of which a total of 2,468 were genotyped on the 
Exome-Chip and passed QC for inclusion into this analysis. 
 
Anglo-Scandinavian Cardiac Outcome Trial [UK/Ireland] (ASCOT-UK) 
ASCOT is a randomised control clinical trial investigating the cardiac outcomes of blood pressure lowering and lipid lowering treatments
23
. Of 
19,342 hypertensive patients (40–79 years of age with at least three other cardiovascular risk factors) who were randomized to one of two 
antihypertensive regimens in ASCOT, 10,305 with non-fasting TC concentrations of 6.5 mmol/l or less (measured at the non-fasting screening 
visit) had been randomly assigned additional atorvastatin 10 mg or placebo. These patients formed the lipid-lowering arm of the study. Only a 
proportion of United Kingdom, Irish, Sweden, Norway, Finland and Denmark consented to contribute DNA and participate in genetic studies. 
Blood lipid levels used in this analysis were measured at the (fasting) randomization visit and LDL- C was estimated using the Friedewald 
equation. The ASCOT-UK sample analysed here is restricted to the patients from UK and Ireland, of which a total of 3,246 were genotyped on the 
Exome-Chip and passed QC for inclusion into this analysis. 
 
Italian Atherosclerosis, Thrombosis, and Vascular Biology Working Group (ATVB-Cases, ATVB-Controls)  
ATVB is a nationwide prospective case control study involving 1,693 patients hospitalised for a first ST segment elevation MI before the age of 
45 years, and 1,668 healthy subjects matched for age, gender and geographical origin
24
. 
 
The BioImage Study (BioImage-African, BioImage-Asian, BioImage-European, BioImage-Hispanic) 
The BioImage Study (BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population, NCT00738725), a 
prospective, observational study aimed at characterizing subclinical atherosclerosis in U.S. adults (55 to 80 years old) at risk for clinical 
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atherosclerotic cardiovascular disease
25
. Between January 2008 and June 2009, the BioImage Study enrolled 7,687 asymptomatic men 55 to 80 
years of age and women 60 to 80 years of age who were members of the Humana Health System and residents of the Chicago, Illinois, or Fort 
Lauderdale, Florida, metropolitan areas. A total of 6,397 individuals with exome chip genotypes and plasma lipids were analyzed. 
 
Vanderbilt University electronic medical record-linked DNA repository (BioVU) 
Vanderbilt University Medical Center Biorepository, BioVU, links DNA samples extracted from discarded blood samples from routine clinical 
testing at Vanderbilt University hospital to de-identified electronic medical records where individual level data can be extracted (e.g. cholesterol 
levels) and analyzed
26,27
.  For the present study, we identified a total of 14156 individuals of European American ancestry with available 
information on LDL, HDL, total cholesterol, or triglyceride levels. 
 
Bangladesh Risk of Acute Vascular Events study (BRAVE_Cases, BRAVE_Controls) 
BRAVE is a retrospective case-control study of first-ever confirmed acute myocardial infarction (MI) in Bangladesh
28
. Patients (male or female; 
age between 30-80 years) admitted to the emergency rooms of the collaborating hospital in Dhaka, Bangladesh were eligible for inclusion as MI 
cases on the basis of symptoms, ECG and troponin-I. Controls were hospital based and frequency-matched to cases on age (within 5 year age 
bands) and sex, and without a self-reported history of cardiovascular disease. Commercial assay kits manufactured by Roche Diagnostics (GmbH, 
D-68298 Mannheim, Germany) were used to determine total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, 
and triglycerides. All analyses were done on Roche automated clinical chemistry analysers, Hitachi 902, Hitachi Ltd, Tokyo, Japan. 
 
British Genetics of Hypertension Study (BRIGHT) 
Participants of the BRIGHT Study are recruited from the Medical Research Council General Practice Framework and other primary care practices 
in the UK
29
. Each case had a history of hypertension diagnosed prior to 60 years of age with confirmed blood pressure recordings corresponding to 
seated levels >150/100mmHg (1 reading) or mean of 3 readings >145/95 mmHg. BRIGHT is focused on recruitment of hypertensive individuals 
with BMI<30. Sample selection for Exome Chip study was based on DNA availability and quantity. 
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The Coronary Artery Risk Development in Young Adults study (CARDIA-white, CARDIA-black) 
The Coronary Artery Risk Development in Young Adults study is a prospective multi-center investigation of the etiology and natural history of 
cardiovascular disease initiated in 1985-1986. The study’s initial enrollment consisted of 5115 European American and African American men and 
women between 18 and 30 years old (52% African American and 55% women) recruited from 4 field centers (Birmingham, AL; Chicago, IL; 
Minneapolis, MN; and Oakland, CA). The institutional review board at each of the study sites approved the study protocols, and written informed 
consent was obtained from all participants. Detailed information about the CARDIA study design and methods of data collection have been 
previously published
30. Briefly, participants’ age, race, and sex were self-reported during the recruitment phase and verified during the baseline 
clinic visit. Blood pressure was measured at the baseline examination on the right arm using a random-zero sphygmomanometer with the 
participant seated and following a 5 minute rest. Systolic and diastolic pressures were recorded as Phase I and Phase V Korotkoff sounds. Three 
measurements were taken at one minute intervals. The average of the second and third measurements was taken as the blood pressure value. The 
present analysis included 4,151 individuals (2,175 European Americans and 1,976 African Americans) with baseline BP measures and genotype 
data. 
 
Copenhagen City Heart Study (CCHS) 
CCHS is a population-based prospective study initiated in 1976 with follow-up examinations from 1981 to 1983, 1991 to 1994, and 2001 to 2003
31
. 
Participants were selected on the basis of the national Danish Civil Registration System to reflect the adult Danish population age 20 to ≥80 years. 
Non-fasting plasma levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides and glucose were measured using 
colorimetric assays.  
 
Copenhagen General Population Study (CGPS) 
The CGPS is a population-based prospective study initiated in 2003 with ongoing enrollment
32,33
. Participants were selected on the basis of the 
national Danish Civil Registration System to reflect the adult Danish population age 20 to ≥80 years. Data were obtained from a questionnaire, a 
physical examination, and blood samples including deoxyribonucleic acid extraction. Non-fasting plasma levels of total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), triglycerides and glucose were measured in fresh samples using colorimetric assays. 
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Cardiovascular Health Study (CHS-EA, CHS-AA) 
The CHS is a population-based cohort study of risk factors for coronary heart disease and stroke in adults ≥65 years conducted across four field 
centers
34
. The original predominantly Caucasian cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare 
eligibility lists, and an additional 687 African-Americans were enrolled subsequently for a total sample of 5,888. DNA was extracted from blood 
samples drawn on all participants at their baseline examination in 1989-90. 750 African-American and 4,021 European- American individuals 
were genotyped using the IlluminaHumanExomeBeadChip array. CHS was approved by institutional review committees at each field center and 
individuals in the present analysis had available DNA and gave informed consent including consent to use of genetic information for the study of 
cardiovascular disease. 
 
Copenhagen Ischemic Heart Disease Study (CIHDS) 
This study comprised 5185 cases with myocardial infarction and other major acute coronary syndromes recruited from Copenhagen University 
Hospital during the period from 1991 to 2009
32,33
. In addition to a diagnosis of acute coronary syndrome, these cases also had stenosis or 
atherosclerosis on coronary angiography and/or positive results on exercise electrocardiography. Cases were classified by World Health 
Organization International Classification of Diseases-Eighth Revision, codes 410 to 414; International Classification of Diseases-Tenth Revision, 
codes I20 to I25, and through review of all hospital admissions and diagnoses entered in the national Danish Patient Registry and all causes of 
death entered in the national Danish Causes of Death Registry. Non-fasting plasma levels of total cholesterol, high-density lipoprotein cholesterol 
(HDL-C), triglycerides and glucose were measured in fresh samples using colorimetric assays. 
 
CROATIA-Korcula (CROATIA-Korcula) 
The CROATIA-Korcula study, Croatia, is a family-based, cross-sectional study in the isolated island of Korcula that included 965 examinees aged 
18-95
35
. Blood samples were collected in 2007 along with many clinical and biochemical measures and lifestyle and health questionnaires. In the 
present study 855 genotyped individuals were included in the analysis. 
 
DIABNORD (Exome Chip) (DIABNORD) 
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The DIABNORD Study is nested within the Västerbotten Health Survey, which is part of the Northern Sweden Health and Disease Study, a 
population-based prospective cohort study from northern Sweden
36
. Participants with incident type 2 diabetes were identified from the Diabetes 
Register in Northern Sweden (DiabNorth). A total of 909 Caucasian, non-diabetic participants from the DIABNORD Study had complete 
genotype and phenotype data necessary for the current analyses. Capillary blood was drawn following an overnight fast. Fasting serum lipid 
concentrations were measured with a Reflotron bench-top analyzer (Roche Diagnostics Scandinavia AB). Participants were genotyped with 
IlluminaHumanExomeBeadchip 12 v1.1. Ethical approval for the DIABNORD Study was obtained from the Regional Ethical Review Board in 
Umeå, Sweden. 
 
Diabetes register in Vasa (DIREVA) 
DIREVA (Diabetes register in Vasa) is a regional project in western Finland. All diabetes patients at all ages in the Vasa region are included. The 
aim of the registry is to describe the spectrum of diabetes subgroups in western Finland and to link genetic and phenotypic information at 
diagnosis of diabetes to outcome data and data on response to treatment. The study is coordinated by the Central hospital in Vasa. 
 
The Finnish Diabetes Prevention Study (DPS) 
DPS is a prospective randomized controlled trial aimed at preventing the progression from IGT to diabetes
37
. The original DPS was initiated in 
1993. A total of 522 middle-aged, overweight subjects with IGT at baseline were randomized into either a lifestyle intervention or a standard-care 
control group. They were followed for occurrence of diabetes until the year 2000, when the first interim analysis of the data was carried out as 
originally planned. At this point, the randomized trial was prematurely terminated due to markedly lower diabetes incidence rate in the lifestyle 
intervention group as compared to the control group. Since the termination of the randomized phase of the DPS, the original cohorts are no longer 
offered different treatments. However, all participants are monitored with yearly visits for long-term development of type 2 diabetes and 
complications. 
 
The Dose Responses to Exercise Training Study (DR's EXTRA) 
DR's EXTRA is a 4-year randomized controlled trial on the health effects of aerobic and resistance exercise training and a diet with low saturated 
fat, high unsaturated fat, and high fiber in a population sample of middle-aged and older men and women
38
. The target population was a 
representative sample of 3,000 individuals (1,500 men, 1,500 women) who lived in the city of Kuopio in Finland and who were 55-74 years of age 
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in 2002, when they were randomly selected from the national population register. Of these individuals, 2,062 were willing to participate and 1,479 
(72%) participated in the baseline examinations in 2005-2006. 1,410 individuals were randomly allocated into one of the six study groups, each of 
which included about 235 persons. 
 
Duke Catheterization Genetics (Duke-AA-Cases, Duke-AA-Controls, Duke-EA-Cases, Duke-AA-Controls) 
The Duke CATHGEN cohort consists of samples collected from individuals undergoing cardiac catheterization at Duke University Medical Center 
between 2001 and 2010
39
. These samples were matched with the findings of coronary anatomy, fasting chemistry data, as well as development of 
health habits and cardiovascular disease later in life through follow-up questionnaires. The data on the absence or presence of coronary artery 
disease were used in this analysis. 
 
The Exeter Family Study of Childhood Health (EFSOCH) 
The Exeter Family Study of Childhood Health is a prospective study, set up to test the fetal insulin hypothesis, and to identify genetic 
polymorphisms that play a role in determining birth weight and early postnatal growth
40
. We recruited 1017 families from a postcode-defined area 
in central Exeter. Specific inclusion criteria were established to obtain a homogeneous, non-diabetic, UK Caucasian cohort. Detailed 
anthropometric measurements were taken from both parents at 28 weeksÕ  gestation, and from their children at birth, 12 weeks, 1 year and 2 years 
of age. Insulin and other biochemical analysis were measured in fasting parental samples and an umbilical cord blood sample taken at delivery. 
Parental and offspring DNA were extracted to allow molecular genetic analysis of candidate genes implicated in fetal growth.  
 
Estonian Genome Center, University of Tartu (EGCUT) 
The Estonian cohort is from the population-based biobank of the Estonian Genome Project of University of Tartu (EGCUT)
41
. The whole project 
is conducted according to the Estonian Gene Research Act and all participants have signed the broad informed consent. The current cohort size is 
over 51,515, from 18 years of age and up, which reflects closely the age distribution in the adult Estonian population. Subjects are recruited by the 
general practitioners and physicians in the hospitals were randomly selected from individuals visiting general practitioners offices or hospitals. 
Each participant filled out a Computer Assisted Personal interview during 1-2 hours at a doctor’s office, including personal data (place of birth, 
place(s) of living, nationality etc.), genealogical data (family history, three generations), educational and occupational history and lifestyle data 
(physical activity, dietary habits, smoking, alcohol consumption, women’s health, quality of life). All diseases are defined according to the ICD10 
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coding. Lipids for current study where directly measured in clinical setting, both phenotype and genotype where available for 1,405 Estonian 
Biobank participants. 
 
European Prospective Investigation into Cancer and Nutrition  - Cardiovascular Disease Study (EPIC-CVD) 
EPIC is a multi-centre prospective cohort study of 519,978 participants (366,521 women and 153,457 men, mostly aged 35–70 years) recruited 
between 1992 and 2000 in 23 centres located in 10 European countries
42
. Participants were invited mainly from population-based registers 
(Denmark, Germany, certain Italian centres, the Netherlands, Norway, Sweden, UK). Other sampling frameworks included: blood donors (Spain 
and Turin and Ragusa in Italy); screening clinic attendees (Florence in Italy and Utrecht in the Netherlands); people in health insurance 
programmes (France); and health conscious individuals (Oxford, UK). About 97% of the participants were of white European ancestry. EPIC-
CVD employs a nested case-cohort design, analogous to the EPIC-InterAct study for type-2 diabetes, which established a common set of referents 
through selection of a random sample of the entire cohort (“subcohort”). Baseline measurements of all serum biomarkers were performed using a 
Roche MODULAR ANALYTICS EVO analyser by SHL groep in the Netherlands.  
 
EPIC-InterAct (EPIC-InterAct T2D cases) 
The InterAct study is a case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts, and 
includes 12,403 incident cases of T2D and a subcohort of 16,154 individuals (including 778 randomly selected incident T2D cases)
43
. Up to 2,192 
incident cases of T2D were included in the current analysis.  
 
Family Heart Study (FamHS-EA) 
The collection of phenotypes and covariates as well as clinical examination have been previously described (https://dsgweb.wustl.edu/fhscc/)
44
. In 
brief, the FamHS began in 1992 with the ascertainment of 1,200 families, half randomly sampled and half selected because of an excess of CHD 
or risk factor abnormalities as compared with age- and sex-specific population rates. The families, with approximately 6,000 European descent 
subjects, were sampled from four population-based parent studies: the Framingham Heart Study, the Utah Family Tree Study, and two centers for 
the ARIC study. Informed consent was obtained from all participants, and this project was approved by the Institutional Review Boards of all 
participating institutions. The participants attended a clinic visit between the years 1994-1996 and a broad range of phenotypes was assessed in the 
general domains of CHD, atherosclerosis, cardiac and vascular function, inflammation and hemostasis, lipids and lipoproteins, blood pressure, 
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diabetes and insulin resistance, pulmonary function, diet, habitual physical activity, anthropometry, medical history and medication use. 
Approximately 8 years later, 2,756 subjects belonging to the 510 of the largest and most informative pedigrees were invited for a second clinical 
exam (2002-2004). The most important CHD risk factors were measured again. Medical history and medication use were updated. A total of 3,794 
subjects from the first clinical visit participated in the current study. The subjects were genotyped using the IlluminaInfiniumHumanExome v1.0 
BeadChip. 
  
The Fenland Study (Fenland) 
The Fenland Study is an ongoing, population-based cohort study (started in 2005) designed to investigate the association between genetic and 
lifestyle environmental factors and the risk of obesity, insulin sensitivity, hyperglycemia and related metabolic traits in men and women aged 30 to 
55 years
45
. Potential volunteers were recruited from General Practice sampling frames in the Fenland, Ely and Cambridge areas of the 
Cambridgeshire Primary Care Trust in the UK. Exclusion criteria for the study were: prevalent diabetes, pregnant and lactating women, inability to 
participate due to terminal illness, psychotic illness, or inability to walk unaided. All participants had measurements done at the MRC 
Epidemiology Unit Clinical Research Facilities in Ely, Wisbech and Cambridge. Participants attended after an overnight fast for a detailed clinical 
examination, and blood samples were collected. The Local Research Ethics Committee granted ethical approval for the study and all participants 
gave written informed consent. 
 
Framingham Heart Study (FHS) 
The FHS is a three generational prospective cohort that has been described in detail previously
46
. Individuals were initially recruited in 1948 in 
Framingham, USA to evaluate cardiovascular disease risk factors. The second generation cohort (5,124 offspring of the original cohort) was 
recruited between 1971 and 1975. The third generation cohort (4,095 grandchildren of the original cohort) was collected between 2002 and 2005. 
Fasting lipid levels were measured at exam 1 of the Offspring (1971-1975) and third generation (2002-2005) cohorts, using standard LRC 
protocols. 8,153 European-American individuals were genotyped using the IlluminaHumanExomeBeadChip array.  
 
FIN-D2D 2007 (FIN-D2D 2007) 
The purpose of the study is to gather information about prevalence of diabetes and cardiovascular diseases and of the risk factors associated with 
these within the Finnish population
47
. The survey assists in the evaluation of the effects of the national type 2 diabetes prevention plan. The study 
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sample consists of 4,500 people randomly selected from the Finnish population register between the ages of 45 and 74 years and living in one of 
the three hospital districts chosen for the study: South Ostrobothnia, Central Finland, and Pirkanmaa. 
 
National FINRISK 2007 Study (FINRISK 2007 T2D cases, FINRISK 207 T2D controls) 
The Finnish National Public Health Institute performed the FINRISK health study in five areas of Finland during spring 2007 to investigate the 
people’s health behavior and the risk factors of chronic diseases and public health problems48. The survey is a continuation of a series of studies 
begun in Eastern Finland in 1972 and performed once every five years since then. The purpose of the study is to gather information about the 
protective and risk factors of the major Finnish public health problems, such as cardiovascular diseases, diseases of the brain and the central 
nervous system, cancers, diabetes, asthma and allergies, and the prevalence of those factors in the population. The survey also monitors the state of 
health of the Finnish population. 
 
Finland-United States Investigation of NIDDM Genetics Study (FUSION T2D cases, FUSION T2D controls) 
FUSION1 cases included FUSION samples each reporting at least one T2D sibling and Finrisk 2002 T2D cases from a Finnish population-based 
risk factor survey
49,50
. Controls included 219 subjects from Vantaa, Finland who were NGT at ages 65 and 70 years, NGT spouses of FUSION 
subjects, and Finrisk 2002 NGT subjects.  FUSION1 controls were approximately frequency-matched to the cases by five-year age category, sex, 
and birth province. FUSION2 includes subjects chosen from the following studies: Dehko 2D (D2D) 2004: a population-based study to screen 
individuals regarding T2D risk and to prevent T2D development; Finrisk 1987: an early round of the 5-yearly Finrisk national population-based 
health surveys; Finrisk 2002: a population-based survey of non-communicable diseases in >13,000 individuals aged 25-74 years living in 80 
communities of Finland; Action LADA: a study of latent autoimmune diabetes in adults (LADA). Action LADA investigators screened 
individuals aged 30-69 years with recently-diagnosed diabetes and identified 373 T2D cases who agreed to participate in FUSION; Health 2000: a 
population-based study of people aged ≥30 years from throughout Finland; Savitaipale Diabetes Study: a study of diabetes in the town of 
Savitaipale in eastern Finland.  
 
Gene x Lifestyle Interactions and Complex Traits Involved in Elevated Disease Risk (Exome Chip) (GLACIER) 
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The Gene-Lifestyle interactions And Complex traits Involved in Elevated disease Risk (GLACIER) Study is nested within the Västerbotten Health 
Survey, which is part of the Northern Sweden Health and Disease Study, a population-based prospective cohort study from northern Sweden
36
. A 
total of 921 Caucasian, non-diabetic participants from the GLACIER Study had complete genotype and phenotype data necessary for the current 
analyses. Capillary blood was drawn following an overnight fast. Fasting serum lipid concentrations were measured with a Reflotron bench-top 
analyzer (Roche Diagnostics Scandinavia AB). Participants were genotyped with IlluminaHumanExomeBeadchip 12 v1.1. Ethical approval for the 
GLACIER Study was obtained from the Regional Ethical Review Board in Umeå, Sweden. 
 
Genetics of Diabetes Audit and Reasearch in Tayside Scotland study (GoDARTS_CAD) 
A high quality resource, initially funded by the Wellcome Trust and supported by Diabetes UK, has been created with successful recruitment of 
consented patients with type 2 diabetes and matching controls (non diabetics) throughout Tayside, Scotland
51
. This resource is already available to 
researchers worldwide and is helping to define genetic factors related to diabetes including susceptibility, complications and response to treatment. 
This analysis used the coronary artery disease subset of the cohort. First-ever CAD event. Defined as fatal and non-fatal myocardial infarction, 
unstable angina or coronary revascularisation. Controls were free of coronary artery disease, stroke and peripheral vascular disease.  
 
Genetics of Diabetes Audit and Research Tayside (GoDARTS-cases, GoDARTS-controls) 
A high quality resource, initially funded by the Wellcome Trust and supported by Diabetes UK, has been created with successful recruitment of 
consented patients with type 2 diabetes and matching controls (non diabetics) throughout Tayside, Scotland
51
. 
 
Genetic regulation of arterial pressure in humans in the community (GRAPHIC) 
The Genetic Regulation of Arterial Pressure in Humans in the Community (GRAPHIC) Study is a family based population study comprising of 
510 nuclear families (two parents aged 40-60 years at recruitment and two adult offspring aged 18-40 years) recruited through primary care in 
Leicestershire between 2003 and 2005
52
. All subjects are of white European origin. The primary objective of the GRAPHIC study was to 
investigate the genetic basis of blood pressure variation and all subjects underwent 24-hour ambulatory BP measurements. In addition, all subjects 
had extensive phenotyping including a full medical history and recording of risk factors and medication, dietary history, physical activity 
assessment, clinic BP, 12 lead ECG, measurement of height, weight, WHR and skinfold thickness. Available laboratory data include serum and 
urine electrolytes, plasma lipids measured by NMR and CRP. A total of 1851 subjects were included in this analysis. 
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Generation Scotland_Scottish Family Health Study (GS-SFHS) 
Generation Scotland-SFHS recruited almost 24,000 participants from throughout Scotland. The study enlisted individuals aged 18-65 and their 
family members. Volunteers were asked to provide information about their lifestyle and diet, their medical history, and samples of blood and urine. 
Participation was by invitation through local GPs, or families volunteering directly. As the name suggests, the SFHS is based on families so at 
least one brother or sister of the initial recruit was required and preferably other family members. In the present study 9946 genotyped individuals 
were included in analysis.  
 
Health2006/Health2008 (Health) 
The Health2006 and Health2008 studies are cohort studies of adults aged 18-69 years who live in the greater Copenhagen area
53
. The aim of the 
studies was to identify lifestyle related risk factors for chronic diseases such as diabetes, heart disease, asthma, musculoskeletal disorders, chronic 
lung disease and mental disorders. Potential participants were excluded if they emigrated from the study location. Baseline examinations were 
conducted between 2006 and 2008. Data is collected through two questionnaires pertaining to lifestyle factors and mental health, and through 
medical exams assessing lung and cardiopulmonary function, and muscle strength. Blood samples were also collected from each participant for 
genetic and/or biomarker studies. The studies were approved by the Ethical Committee of Copenhagen County and the Danish Data Protection 
Agency. Here 3616 participants with information on lipids and exome chip were analysed. 
 
Hellenic Isolated Cohorts - MANOLIS cohort (HELIC MANOLIS) 
The HELIC (Hellenic Isolated Cohorts; www.helic.org) MANOLIS (Minoan Isolates) collection focuses on the Mylopotamos villages. 
Recruitment of this population-based sample was primarily carried out at the village medical centres. All individuals were older than 17 years and 
had to have at least one parent from the Mylopotamos area. The study includes biological sample collection for DNA extraction and lab-based 
blood measurements, and interview-based questionnaire filling. The phenotypes collected include anthropometric and biometric measurements, 
clinical evaluation data, biochemical and haematological profiles, self-reported medical history, demographic, socioeconomic and lifestyle 
information. The study was approved by the Harokopio University Bioethics Committee and informed consent was obtained from every 
participant. The total sample size in the collection is approximately 1,500 and 825 individuals genotyped on the exome chip and with lipid data 
available were included in this analysis.  
 24 
 
Hellenic Isolated Cohorts - Pomak cohort (HELIC Pomak) 
The HELIC (Hellenic Isolated Cohorts; www.helic.org) Pomak collection focuses on the Pomak villages, a set of isolated mountainous villages in 
the North of Greece. Recruitment of this population-based sample was primarily carried out at the village medical centres. The study includes 
biological sample collection for DNA extraction and lab-based blood measurements, and interview-based questionnaire filling. The phenotypes 
collected include anthropometric and biometric measurements, clinical evaluation data, biochemical and haematological profiles, self-reported 
medical history, demographic, socioeconomic and lifestyle information. The study was approved by the Harokopio University Bioethics 
Committee and informed consent was obtained from every participant. The total sample size in the collection is approximately 1,700 and 971 
individuals genotyped on the exome chip and with lipid data available were included in this analysis.  
 
The Nord-Trondelag Health Study (HUNT-Case) 
We included 5,440 individuals with at least one lipid measurement from the second survey of the Nord-Trondelag Health Study (HUNT):  2,662 
cases with hospital diagnosed myocardial infarction (primary phenotype) and 2,778 healthy controls without cardiovascular disease matched on 
sex, birth year (+/- 1 year), and municipality or geographical region to minimize population stratification
54
.  HUNT is a population based health 
study (www.ntnu.edu/hunt) with personal and family medical histories on approximately 120,000 individuals from Nord-Trondelag County, 
Norway, collected in three surveys (HUNT 1, 2, and 3). Self-reported questionnaires, clinical examination, and non-fasting venous blood samples 
were collected on 62,816 individuals (66.9% of invited).   
 
The Nord-Trondelag Health Study (HUNT-Control) 
We included 5,440 individuals with at least one lipid measurement from the second survey of the Nord-Trondelag Health Study (HUNT):  2,662 
cases with hospital diagnosed myocardial infarction (primary phenotype) and 2,778 healthy controls  without cardiovascular disease matched on 
sex, birth year (+/- 1 year), and municipality or geographical region to minimize population stratification
54
.  HUNT is a population based health 
study with personal and family medical histories on approximately 120,000 individuals from Nord-Trondelag County, Norway, collected in three 
surveys (HUNT 1, 2, and 3)19,35.  HUNT 2 was conducted in 1995-97, inviting all residents ³ 20 years of age in Nord-Tr¿ndelag County, Norway.  
Self-reported questionnaires, clinical examination, and non-fasting venous blood samples were collected on 62,816 individuals (66.9% of invited). 
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Inter99 (Inter99) 
The Inter99 study carried out in 1999-2001 included invitation of 12934 persons aged 30-60 years drawn from an age- and sex-stratified random 
sample of the population
55
. The baseline participation rate was 52.5%, and the study included 6784 persons. The Inter99 study was a population-
based randomized controlled trial (CT00289237, ClinicalTrials.gov) and investigated the effects of lifestyle intervention on CVD. Here 5827 
participants with information on lipids and exome chip were analysed. 
 
The Mount Sinai BioMeBiobank (IPM BioMe-African, IPM BioMe-European, IPM BioMe-Hispanic) 
The BioMeBiobank is an ongoing, prospective, hospital- and outpatient- based population research program operated by The Charles Bronfman 
Institute for Personalized Medicine (IPM) at Mount Sinai. BioMe has enrolled over 33,000 participants between September 2007 and December 
2015. BioMe is an Electronic Medical Record (EMR)-linked biobank that integrates research data and clinical care information for consented 
patients at The Mount Sinai Medical Center, which serves diverse local communities of upper Manhattan with broad health disparities. IPM 
BioMe populations include 25% of African American ancestry (AA), 36% of Hispanic Latino ancestry (HL), 30% of white European ancestry 
(EA), and 9% of other ancestry. The IPM BioMe disease burden is reflective of health disparities in the local communities. BioMe operations are 
fully integrated in clinical care processes, including direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicated 
BioMe recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. Recruitment currently occurs at a 
broad spectrum of over 30 clinical care sites.  Information on anthropometrics, demographics, lipid levels and use of lipid-lowering medication 
was derived from participants’ EMR. 
 
Jackson Heart Study (JHS) 
The JHS is a large, population-based observational study evaluating the etiology of cardiovascular, renal, and respiratory diseases among African 
Americans residing in the three counties (Hinds, Madison, and Rankin) that make up the Jackson, Mississippi metropolitan area
56
. Data and 
biologic materials have been collected from 5301 participants, including a nested family cohort of 1,498 members of 264 families. The age at 
enrollment for the unrelated cohort was 35-84 years; the family cohort included related individuals >21 years old. Participants provided extensive 
medical and social history, had an array of physical and biochemical measurements and diagnostic procedures, and provided genomic DNA during 
a baseline examination (2000-2004) and two follow-up examinations (2005-2008 and 2009-2012). The study population is characterized by a high 
prevalence of diabetes, hypertension, obesity, and related disorders. Annual follow-up interviews and cohort surveillance are ongoing. 2,154 
 26 
African-American individuals were genotyped using the IlluminaHumanExomeBeadChip array. Individuals that overlapped with ARIC were 
randomly split between the two cohorts, except individuals in a known JHS family were kept in JHS. 
 
KooperativeGesundheitsforschung in der Region Augsburg (KORA) 
The KORA Study is a series of population-based epidemiological surveys of persons living in or near the city of Augsburg, Germany
57,58
. All 
survey participants are residents of German nationality identified through the registration office and between 25 and 75 years old at the time of 
enrollment. Survey S4 was conducted between 1999 and 2001. KORA F4 is a 7-year follow up of S4. IlluminaExome Chip data is available for 
participants from KORA F4. Cryptically related persons have been removed as well as population outliers and non-fasting samples. The final 
study sample consists of 2723 persons. 
 
Lothian Birth Cohort 1921 (LBC 1921)  
The LBC1921 cohort consists of 550 relatively healthy individuals, 316 females and 234 males, assessed on cognitive and medical traits at about 
79 years of age
59,60
. They were all born in 1921 and most took part in the Scottish Mental Survey of 1932. When tested, the sample had a mean age 
of 79.1 years (SD = 0.6). They were all Caucasian, community-dwelling, and almost all lived in the Lothian region (Edinburgh city and 
surrounding area) of Scotland. Genotyping was performed at the Wellcome Trust Clinical Research Facility, Edinburgh using the 
IlluminaHumanExomeBeadChip. 
 
Lothian Birth Cohort 1936 (LBC1936)  
The LBC1936 consists of 1091 relatively healthy individuals assessed on cognitive and medical traits at about 70 years of age
60,61
. They were all 
born in 1936 and most took part in the Scottish Mental Survey of 1947. At baseline the sample of 548 men and 543 women had a mean age 69.6 
years (SD = 0.8). They were all Caucasian, community-dwelling, and almost all lived in the Lothian region (Edinburgh city and surrounding area) 
of Scotland. Genotyping was performed at the Wellcome Trust Clinical Research Facility, Edinburgh using the IlluminaHumanExomeBeadChip.  
 
The London Life Sciences Population Study (LOLIPOP-ExomeChip) 
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LOLIPOP is an ongoing population based cohort study of 17,606 Indian Asian and 7,766 European men and women aged 35-75 years, recruited 
from the lists of 58 General Practitioners in West London, United Kingdom
62
. Participants classified as having Indian Asian ancestry reported 
having all four grandparents born on the Indian subcontinent. Biochemical analysis included total and HDL cholesterol and triglycerides, using 
standard commercial assays. Aliquots of whole blood, plasma and serum are frozen at –80°C. In the present study, 970 and 1,664 Indian Asian 
samples were genotyped on the IlluminaExomChip array and the IlluminaOmniExpressExome array, respectively.  
 
The London Life Sciences Population Study (LOLIPOP-OmniExpressExome) 
LOLIPOP is an ongoing population based cohort study of 17,606 Indian Asian and 7,766 European men and women aged 35-75 years, recruited 
from the lists of 58 General Practitioners in West London, United Kingdom
62
. Participants classified as having Indian Asian ancestry reported 
having all four grandparents born on the Indian subcontinent. Biochemical analysis included total and HDL cholesterol and triglycerides, using 
standard commercial assays. Aliquots of whole blood, plasma and serum are frozen at –80°C. In the present study, 970 and 1,664 Indian Asian 
samples were genotyped on the IlluminaExomChip array and the IlluminaOmniExpressExome array, respectively. 
 
Malmo Diet and Cancer Study (MDC) 
The Malmö Diet Cancer Study is an ongoing longitudinal prospective cohort study of the middle-aged population of Malmö designed to screen for 
dietary habits and genetic markers in order to predict incident cancers in the general population and to screen for cardiovascular risk factors and 
early atherosclerosis in a sub-sample
63
. 28,000 subjects living in Malmö were during 1992-1996 invited by letter to a clinical examination, food-
frequency questionnaire and blood sampling. Individuals were between ages 45-70 at first screening. Self-completed questionnaires, clinical 
examinations, and extracts from registers are available for the years 1992-2009. A subgroup of the patients totaling less than 5,000 individuals 
with complete phenotype data was analyzed as one cohort in this study of plasma lipid levels. 
 
Multi-Ethnic Study of Atherosclerosis  (MESA-EA, MESA-AA, MESA-Chinese, MESA-Hispanic)  
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-
invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular 
disease or progression of the subclinical disease
64
. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and 
women aged 45-84. Thirty-eight percent of the recruited participants are White, 28 percent African-American, 22 percent Hispanic, and 12 percent 
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Asian, predominantly of Chinese descent. 2,128 additional individuals from 594 families were recruited through MESA Family by utilizing the 
existing MESA framework, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans. Participants were recruited from 
six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, 
Northwestern University and University of California - Los Angeles. For the present analyses, we included 2490 White, 2496 African American, 
2081 Hispanic and 701 Chinese participants. 
 
Metabolic Syndrome in Men Study (METSIM) 
The METSIM study aims to investigate the metabolic syndrome, type 2 diabetes, cardiovascular disease, and cardiovascular risk factors
65
. It is an 
ongoing study of men aged 50 to 70 years, randomly selected from the population registry of the town of Kuopio, in Eastern Finland. 
 
Montreal Heart Institute Biobank (MHI Biobank) 
The Montreal Heart Institute (MHI) Biobank is a longitudinal hospital cohort, which was initiated in 2005 with the aim to recruit 30,000 patients 
of the MHI for clinical and genetic research
66
. Participants are recruited from different departments within the MHI and its affiliated prevention 
centre. The MHI Biobank collects data by using a detailed questionnaire administered by a research nurse at baseline including demographics, 
personal and family medical history, diet, tobacco, medication use, as well as depression and hostility questionnaires. Blood, DNA, and plasma are 
collected at baseline and stored at the Beaulieu-Saucier Pharmacogenomics Centre. The patients health information is confirmed and 
complemented by the research nurse from the hospital's health record. The cohort's database is updated daily with patient's medical information 
from the hospital's electronic records including laboratory and lipid measurements and a follow-up study questionnaire is administered every four 
years. The questionnaire is updated every 4 years. The cohort is comprised of over 20,000 participants as of January 2016 with a median follow up 
period of 4.2 years. Genotyping was performed on the first 11,556 participants using the IlluminaHumanExome chip v1.1. Lipid measurements for 
the current project were obtained from the hospital records, by selecting the records with sampling dates that were the closest to that of the 
baseline questionnaire. Following clinical and genetic data cleanup procedures, 6421 patients with both lipid and genotype data were available for 
analysis. 
 
MOnica Risk, Genetics, Archiving and Monograph project (MORGAM) 
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MORGAM is a consortium of prospective cohort studies from around Europe
67
. For this project, participants were included from the ATBC study 
(Finland), Augsburg-KORA (Germany), Brianza (ltaly) and PRIME cohorts Belfast (UK), Lille, Strasbourg and Tolouse (all France). A case-
cohort design was used comparing incident coronary disease cases with participants randomly selected from within each study. Lipids were 
measured at baseline using standard approaches. 
 
Northern Finland Birth Cohort 1986 (NFBC1986) 
The NFBC1986 study includes 9432 live-born individuals with expected dates of birth between July 1st 1985 and June 30th 1986 in the provinces 
of Oulu and Lapland, in Finland. The University of Oulu Ethics Committee and the Ethical Committee of Northern Ostrobothnia Hospital District 
have approved the study. Cohort has been followed up since early pregnancy until adolescence. Growth measurements were obtained from 
communal child health clinics. Samples were stored at -80 ¼ C until analyzed and DNA extracted. Fasting serum total cholesterol and triglycerides 
were determined using an Hitachi 911 automatic analyser and commercial reagents (Roche, Mannheim, Germany). HDL- and LDL-C were also 
determined using the same analyzer and methods previously described (Sugiuchi J et al, 1995, ClinChem; Wieland H et al, 1983, J Lipid Res). The 
intra- and interassay coefficients of variation were 0.7 and 1.5% for total cholesterol, 0.5 and 3.2% for HDL-C, 1.6 and 2.6% for LDL-C, 0.9 and 
2.4% for triglycerides.  
 
Oxford BioBank (OBB) 
The Oxford Biobank is a collection of 30-50 year old healthy men and women living in Oxfordshire. All participants have undergone a detailed 
examination at a screening visit, donated DNA and given informed consent to be re-approached. The Oxford Biobank is a resource for medical 
research to translate early discoveries to the benefit of patients in the future. In the present study, a total of 4442 individuals were inlcuded in the 
analysis (http://www.oxfordbiobank.org.uk/). 
 
Ottawa Heart Study (Ottawa-Cases, Ottawa-Controls) 
The Ottawa Heart Study is an ongoing, hospital-based study of coronary heart disease at the Ottawa Heart Institute in Ottawa, Canada. All patients 
at the Institute who undergo coronary artery bypass grafting, coronary artery angiography, or care for acute myocardial infarction are invited to 
participate in the study. Healthy elderly controls (men > 65y, women > 70y) were recruited via an extensive newspaper and television advertising 
campaign in the Ottawa community. Controls were carefully interviewed by a physician or nurse to ascertain that they were free of symptoms of 
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possible ischemic arterial disease and had no past history of cardiovascular symptoms, a positive stress test, coronary angiography demonstrating 
stenosis (>50%) in any artery or clinical cardiovascular events. Individuals with the same ethnic background as the cases (Caucasian) were 
included in this study (total sample of 1100 cases and 2361 controls). In the present study, a total of 951 cases and 2103 controls were included 
into analysis.  
  
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) / Uppsala Longitudinal Study of Adult Men (ULSAM) (PIVUS-
ULSAM) 
The PIVUS study started in 2001 with the primary aim to investigate the predictive power of different measurements of endothelial function and 
arterial compliance in a random sample of 1000 subjects aged 70 living in the community of Uppsala
68
. ULSAM is a unique, ongoing, longitudinal, 
epidemiologic study based on all available men, born between 1920 and 1924, in Uppsala County, Sweden
69
. The men were investigated at the 
ages of 50, 60, 70, 77, 82 and 88 years. Individuals investigated at age 70 were included in the current analysis.  In the present study a total of 
2006 samples (944 PIVUS / 1062 ULSAM) were included into analysis. 
 
Prevalence, Prediction and Prevention of Diabetes (PPP)-Botnia study 
The Prevalence, Prediction and Prevention of diabetes (PPP)–Botnia Study is a population-based study in Western Finland carried out from 2004 
to 2008 to obtain accurate estimates of prevalence and risk factors for type 2 diabetes, impaired glucose tolerance, impaired fasting glucose and the 
metabolic syndrome in the adult population and to use this information for prediction and prevention of the disease
70
. The participants were 
randomly recruited from the national Finnish Population Registry to represent 6 to 7% of the population in the 18- to 75-year age range. 
Altogether 5,208 individuals participated in the study (54.7% of those invited). 
 
PROCARDIS (Procardis Cases, Procardis Controls) 
The PROCARDIS Study is a an ongoing study of coronary heart disease at multiple centers in Europe (the universities of Oxford and Münster; the 
Karolinska Institute; the Mario Negri Institute; DigilabBioVisioN GmbH; Centre National de Genotypage; Institut de Recerca del Hospital de la 
Santa Creu I Sant Pau; UniversitàdegliStudi di Milano; Clinical Gene Networks AB; CF consulting S.r.l.; Metabometrix Limited) and 
AstraZeneca
71
. Families with members with patients with myocardial infarction or symptomatic acute coronary syndrome occurring before the age 
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of 65 as evidenced by typical clinical symptoms, EKG findings, and biomarker elevation were selected. The study aims to identify new 
susceptibility genes of coronary artery disease through a genome-wide screen. 
 
Pakistan Risk of Myocardial Infarction Study (PROMIS_Cases, PROMIS_Controls) 
PROMIS is a retrospective case-control study of first-ever confirmed acute MI in Pakistan
72
. Patients aged 30-80 years who were admitted to the 
emergency rooms of nine recruitment centres across Pakistan were eligible for inclusion as cases on the basis of symptoms, ECG and troponin 
levels. Controls were hospital based and frequency-matched to cases on age (within 5 year age bands) and sex, and without a self-reported history 
of cardiovascular disease. Nonfasting blood samples were drawn from each participant and centrifuged within 45 minutes of venepuncture. Serum 
samples were stored at -80°C. Total cholesterol, HDL-C, and triglyceride concentrations were measured using enzymatic methods (Roche 
Diagnostics, USA) at the Center for Non-Communicable Diseases, Pakistan.  
 
Prospective Study of Pravastatin in the Elderly at Risk clinical trial (PROSPER) 
PROSPER was a controlled, randomised study involving 2,804 men and 3,000 women aged 70-82, with a history of, or risk factors for 
cardiovascular disease
73
. Participants were randomised to either 40mg pravastatin per day or matching placebo. A nested case-control design was 
used for this study, selecting as cases individuals who self-reported a history of coronary disease at baseline or who had a coronary event during 
follow-up. Controls were participants who were free of cardiovascular disease at baseline and at the end of follow-up, frequency matched to the 
cases for sex and age (in 5-year bands). Baseline lipid levels were measured using standard assays at the Department of Pathological Biochemistry 
at the Glasgow Royal Infirmary.  
 
SardiNIA study on aging (SardiNIA) 
The SardiNIA study is a longitudinal, population-based study that includes 6,921 individuals, representing >60% of the adult population of 4 
villages in the Lanusei valley on Sardinia (Italy)
74
. These individuals are clustered in 1,257 multigenerational families, up to 5 generations deep, 
and have been characterized for hundreds of quantitative traits. All participants gave informed consent to study protocols, which were approved by 
the Sardinian local research ethic committees: ComitatoEtico di Azienda Sanitaria Locale 8, Lanusei (2009/0016600) and ComitatoEtico di 
Azienda Sanitaria Locale 1, Sassari (2171/CE)) and by the NIH Office of Human Subject Research as governed by Italian institutional review 
board approval. 
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Steno Diabetes Center (SDC) 
Patients with T2D (above 18 years of age) were recruited from the outpatient clinic at Steno Diabetes Center, Gentofte, Denmark
75
. 
Anthropometrics and basal fasting biochemistry (e.g. plasma glucose, serum insulin, HbA1C and lipids) have been measured. Here 499 T2D cases 
with information on lipids and exome chip were analysed. 
 
Twins UK (TwinsUK) 
The TwinsUK cohort is an adult twin British registry recruited from the general population in the United Kingdom
76
. In the present study, a total 
of 923 individuals were included into analysis. 
 
VejleBiobank - T2D cases and Controls (VejleCases, VejleControls) 
VejleBiobank is a sample of clinical-onset T2D patients, and non-diabetic control individuals with matched age and gender distribution, examined 
at Vejle Hospital during a three year period
75
. Control individuals were non-diabetic by self-report and according to fasting plasma glucose levels. 
The main objectives of the study were to investigate the development of late diabetic complications and lack of treatment effect. Anthropometrics, 
including body fat percentage, basal fasting biochemistry (e.g. plasma glucose, serum insulin, HbA1C and lipids), detailed biochemistry (e.g. 
measures of kidney function and serum CRP) have been assessed and questionnaires regarding lifestyle, health, diabetic complications and use of 
anti-diabetic medication filled out. Here 1879 T2D cases and 424 T2D controls with information on lipids and exome chip were analysed. 
 
Women's Genome Health Study (WGHS) 
The Women’s Genome Health Study (WGHS) is a prospective cohort of initially healthy, female North American health care professionals at least 
45 years old at baseline representing participants in the Women’s Health Study (WHS) who provided a blood sample at baseline and consent for 
blood-based analyses
77
. The WHS was a 2x2 trial beginning in 1992-1994 of vitamin E and low dose aspirin in prevention of cancer and 
cardiovascular disease with about 10 years of follow-up.  Since the end of the trial, follow-up has continued in observational mode.  
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Women's Health Initiative (WHI-EA, WHI-AA) 
The WHI is one of the largest (n = 161,808) US studies of women’s health. This project was approved by the ethics committee at the Fred 
Hutchinson Cancer Research Center. The WHI consists of 2 main components: (i) a clinical trial that enrolled 68,132 post-menopausal women 
aged 50–79 years and randomized them to 1 of 3 placebo-controlled clinical trials of hormone therapy, dietary modification or supplementation 
with calcium and vitamin D and (ii) an observational study that enrolled 93,676 women of the same age range in a parallel prospective study
78
. 
 
West of Scotland Coronary Prevention Study (WOSCOPS) 
WOSCOPS was a controlled, randomised study involving 6,595 men aged 45-64, with elevated LDL cholesterol but no history of myocardial 
infarction
79
. Participants were randomised to either 40mg pravastatin per day or matching placebo. A nested case-control design was used for this 
study, selecting as cases individuals who had a coronary event during follow-up. Controls were participants who were free of cardiovascular 
disease at baseline and at the end of follow-up, frequency matched to the cases on age (in 5-year bands). Baseline lipid levels were measured using 
enzymatic cholesterol and triglyceride assays at the Department of Pathological Biochemistry at the Glasgow Royal Infirmary.  
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Supplementary Tables 
Supplementary Table 1.  Coverage of exome array for coding variants present in ExAC 
 Polymorphic variants on Asian exome array      Comparison to ExAC sequenced Asian samples  
Variant type 
MAF in exome 
array 
Number of variants 
genotyped by exome 
array 
MAF in ExAC 
Asian 
Number of 
variants identified 
by ExAC 
Number of variants 
identified by exome 
array Percentage 
LoF < 0.01% 2317 1 copy 11139 468 4.20% 
 0.01%~0.1% 863 2 copy~0.1% 3530 520 14.73% 
 0.1%~1% 505 0.1%~1% 1161 567 48.84% 
 1%~5% 117 1%~5% 232 123 53.02% 
 5%~50% 150 5%~50% 280 145 51.79% 
Missense < 0.01% 71212 1 copy 263400 17097 6.49% 
 0.01%~0.1% 39693 2 copy~0.1% 116045 23300 20.08% 
 0.1%~1% 22988 0.1%~1% 40855 24605 60.23% 
 1%~5% 6433 1%~5% 9627 7034 73.07% 
 5%~50% 11288 5%~50% 16725 11954 71.47% 
LoF+Missense < 0.01% 73529 1 copy 274539 17565 6.40% 
 0.01%~0.1% 40556 2 copy~0.1% 119575 23820 19.92% 
 0.1%~1% 23493 0.1%~1% 42016 25172 59.91% 
 1%~5% 6550 1%~5% 9859 7157 72.59% 
 5%~50% 11438 5%~50% 17005 12099 71.15% 
LoF: Loss of function. LoF is defined as stop-gain, stop-loss, or splice site changes. 
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Supplementary Table 2. Association results at 7 previously known loci reaching suggestive significance (P < 4.46 × 10
-6
, 
0.05/11,215) 
Gene Position rsID Alleles Variant ALT.FREQ trait Effect P N 
GALNT2 1:230294916 rs2144300 T/C  0.19 HDL 0.04(0.008) 2.16E-06 47456 
CCHCR1 6:31116210 rs130071 A/G p.Leu482Leu 0.09 TG 0.068(0.014) 6.10E-07 35389 
HLA-DRA 6:32398648 rs3129853 A/G  0.17 TG 0.043(0.009) 3.84E-06 43728 
MIR148A 7:25997536 rs4719841 G/A  0.63 LDL -0.033(0.007) 1.98E-06 44985 
ZNF335 20:44601293 rs16990971 G/A  0.06 TG 0.082(0.017) 1.78E-06 28538 
UBE2L3 22:21928641 rs181359 A/G  0.51 HDL -0.033(0.007) 8.10E-07 45989 
PNPLA3 22:44324727 rs738409 G/C p.Ile148Met 0.36 TG -0.039(0.008) 7.53E-07 35920 
ALT.FREQ, alternative allele frequency. 
Position is reported in human genome build hg19.  
Alleles are listed as alternative / reference allele on the forward strand of the reference genome.  
There are 11,215 polymorphic variants within 500k from the known loci where novariants did reach exome-wide significance with lipid traits. 
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Supplementary Table 4. Association results of multiple independent variants in 12 loci identified by sequential conditional 
analysis 
Gene Trait rsID chrpos.hg19 Allele Variant ALT.FREQ Effect P N index chrpos.hg19.index r2 
APOB LDL rs13306194 2:21252534 A/G p.Arg532Trp 0.12 -0.098(0.01) 9.53E-22 44985 rs1367117 2:21263900 0.016  
  rs376825639 2:21228437 G/A p.Ile3768Thr 0.0015 -0.579(0.098) 3.35E-09 34108   0.001  
 TC rs13306194 2:21252534 A/G p.Arg532Trp 0.12 -0.114(0.01) 1.45E-29 46025   0.016  
  rs376825639 2:21228437 G/A p.Ile3768Thr 0.0015 -0.659(0.097) 8.44E-12 36514   0.001  
HMGCR LDL rs3846663 5:74655726 T/C  0.52 0.07(0.007) 2.60E-25 44985 rs12916 5:74656539 1.000 
  rs191835914 5:74646765 C/A p.Tyr311Ser 0.02 -0.19(0.026) 2.20E-13 43617   0.018 
LPL HDL rs10096633 8:19830921 T/C  0.09 0.165(0.011) 5.78E-47 47456 rs12678919 8:19844222 0.970 
  rs13702 8:19824492 C/T  0.19 0.116(0.009) 4.15E-42 47456   0.427 
ABCA1 HDL rs1883025 9:107664301 T/C  0.23 -0.08(0.008) 1.23E-23 45804 rs1883025 9:107664301 1.000 
  rs2066714 9:107586753 C/T p.Ile883Met 0.71 0.052(0.007) 1.41E-12 47456   0.014 
  rs2230808 9:107562804 C/T p.Lys1587Arg 0.61 0.047(0.007) 2.49E-12 47456   0.003 
APOA5 HDL rs2075291 11:116661392 A/C p.Gly185Cys 0.06 -0.288(0.014) 3.91E-91 47456 rs964184 11:116648917 0.018 
  rs2266788 11:116660686 A/G  0.78 0.106(0.008) 5.07E-40 47456   0.976 
  rs180327 11:116623659 T/C  0.66 0.1(0.009) 3.45E-31 30661   0.543 
  rs12718465 11:116707736 T/C p.Ala61Thr 0.03 -0.116(0.019) 5.50E-10 45989   0.007 
 TG rs651821 11:116662579 T/C  0.73 -0.285(0.009) 3.42E-198 28538   0.692 
  rs2266788 11:116660686 A/G  0.78 -0.209(0.008) 5.40E-139 43728   0.976 
  rs2075291 11:116661392 A/C p.Gly185Cys 0.06 0.363(0.015) 1.12E-131 43728   0.018 
  rs180327 11:116623659 T/C  0.66 -0.178(0.009) 3.10E-88 28538   0.543 
  rs7123454 11:116704178 A/C  0.63 -0.107(0.012) 2.73E-19 15933   0.095 
ACACB TG rs2075260 12:109696838 A/G p.Val2141Ile 0.74 0.043(0.008) 3.95E-08 43728 rs7134594 12:110000193 0.010 
LIPC HDL rs2043085 15:58680954 C/T  0.53 -0.1(0.007) 8.98E-52 47456 rs1532085 15:58683366 0.967 
  rs1800588 15:58723675 T/C  0.39 0.095(0.007) 1.70E-38 39648   0.004 
 TC rs1532085 15:58683366 G/A  0.54 -0.047(0.007) 1.58E-12 46025   1.000 
  rs1800588 15:58723675 T/C  0.39 0.047(0.007) 3.12E-10 38217   0.004 
 TG rs1800588 15:58723675 T/C  0.39 0.066(0.008) 7.62E-18 35920   0.004 
  rs1532085 15:58683366 G/A  0.54 -0.051(0.007) 1.39E-13 43728   1.000 
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CETP HDL rs247616 16:56989590 T/C  0.16 0.235(0.009) 1.66E-156 47456 rs3764261 16:56993324 0.992 
  rs2303790 16:57017292 G/A p.Asp459Gly 0.02 0.407(0.025) 7.53E-62 38181   0.044 
  rs7499892 16:57006590 T/C  0.16 -0.162(0.01) 7.20E-61 38539   0.034 
  rs201790757 16:56997025 G/T p.Tyr74* 0 1.117(0.182) 8.97E-10 47456   0.000 
 TC rs247616 16:56989590 T/C  0.16 0.065(0.009) 2.65E-13 46025   0.992 
  rs7499892 16:57006590 T/C  0.16 -0.066(0.01) 2.24E-11 38574   0.034 
PKD1L3 TC rs7185272 16:72013797 C/G p.Thr429Ser 0.74 0.054(0.008) 1.65E-12 45494 rs2000999 16:72108093 0.031 
  rs17358402 16:71967927 T/C p.Arg1572His 0.05 0.088(0.015) 1.96E-09 46025   0.002 
 LDL rs7185272 16:72013797 C/G p.Thr429Ser 0.74 0.059(0.008) 4.87E-14 43086   0.031 
  rs17358402 16:71967927 T/C p.Arg1572His 0.05 0.088(0.015) 2.11E-08 43617   0.002 
LIPG HDL rs4939883 18:47167214 C/T  0.82 0.064(0.009) 1.23E-13 45989 rs7241918 18:47160953 0.595 
  rs2000813 18:47093864 T/C p.Thr111Ile 0.31 0.043(0.007) 1.04E-09 47456   0.008 
APOE HDL rs769449 19:45410002 A/G  0.09 -0.108(0.012) 2.48E-19 44817 rs4420638 19:45422946 0.617 
  rs7412 19:45412079 T/C p.Arg176Cys 0.09 0.104(0.016) 3.95E-11 25746   0.008 
 LDL rs445925 19:45415640 A/G  0.09 -0.408(0.012) 1.12E-275 44985   0.006 
  rs7412 19:45412079 T/C p.Arg176Cys 0.09 -0.472(0.016) 4.87E-197 25730   0.008 
  rs769449 19:45410002 A/G  0.09 0.14(0.012) 4.36E-30 42445   0.617 
  rs4420638 19:45422946 G/A  0.12 0.085(0.015) 3.27E-08 20114   1.000 
 TC rs445925 19:45415640 A/G  0.09 -0.246(0.011) 2.39E-103 46025   0.006 
  rs7412 19:45412079 T/C p.Arg176Cys 0.09 -0.281(0.016) 1.46E-71 25904   0.008 
  rs2075650 19:45395619 G/A  0.09 0.116(0.011) 1.82E-24 46025   0.489 
 TG rs439401 19:45414451 C/T  0.43 0.069(0.007) 2.18E-23 43728   0.146 
  rs445925 19:45415640 A/G  0.09 0.115(0.012) 9.53E-23 43728   0.006 
  rs769449 19:45410002 A/G  0.09 0.103(0.012) 4.32E-17 42556   0.617 
  rs4420638 19:45422946 G/A  0.12 0.081(0.015) 1.57E-07 19977   1.000 
LDLR LDL rs200990725 19:11217315 T/C p.Arg257Trp 0 0.882(0.109) 6.35E-16 44985 rs6511720 19:11202306 0.000 
  rs11557092 19:11257018 C/T  0.75 0.06(0.008) 9.65E-15 44985   0.003 
 TC rs11557092 19:11257018 C/T  0.75 0.051(0.008) 3.18E-11 46025   0.003 
    rs200990725 19:11217315 T/C p.Arg257Trp 0 0.677(0.109) 5.57E-10 46025   0.000 
ALT.FREQ, alternative allele frequency. Position is reported in human genome build hg19.  
Alleles are listed as alternative / reference allele on the forward strand of the reference genome.  
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Supplementary Table 5. Genes with a Burden of Rare or Low-Frequency Variants Significantly Associated with lipid levels 
Gene Trait N P 
No. of 
variants 
beta se Best tests Coding variants 
PCSK9 LDL 44985 2.60E-83 16 -0.374 0.024 SKAT,0.05 1:55505647/G/T,1:55509585/C/T,1:55517953/G/A,1:
55518085/G/T,1:55518371/G/A,1:55518419/G/A,1:55
521713/C/A,1:55523178/C/A,1:55523802/A/G,1:5552
3855/G/A,1:55524222/C/T,1:55524237/G/A,1:555243
09/G/A,1:55525301/G/A,1:55527093/C/T,1:55529108
/G/A 
 TC 46025 2.79E-76 15 -0.345 0.024 SKAT,0.05 1:55505647/G/T,1:55509585/C/T,1:55517953/G/A,1:
55518085/G/T,1:55518371/G/A,1:55518419/G/A,1:55
521713/C/A,1:55523178/C/A,1:55523855/G/A,1:5552
4222/C/T,1:55524237/G/A,1:55524309/G/A,1:555253
01/G/A,1:55527093/C/T,1:55529108/G/A 
EVI5 TC 46025 3.32E-08 21 0.157 0.028 GRANVIL,0.01 1:92979254/G/A,1:92979520/C/T,1:93089742/C/G,1:
93089862/C/G,1:93089890/C/T,1:93089891/G/A,1:93
101886/C/G,1:93131510/C/T,1:93131543/G/A,1:9314
2746/G/A,1:93159398/G/T,1:93159438/G/C,1:931594
50/G/C,1:93159927/G/A,1:93160880/A/G,1:9316089
2/C/T,1:93163431/C/T,1:93163436/T/C,1:93163460/
G/A,1:93167754/G/A,1:93201961/T/C 
 LDL 44985 1.37E-07 22 0.146 0.029 SKAT,0.01 1:92979254/G/A,1:92979520/C/T,1:93070892/C/T,1:
93089742/C/G,1:93089862/C/G,1:93089890/C/T,1:93
089891/G/A,1:93101886/C/G,1:93131510/C/T,1:9313
1543/G/A,1:93142746/G/A,1:93159398/G/T,1:931594
38/G/C,1:93159450/G/C,1:93159927/G/A,1:93160880
/A/G,1:93160892/C/T,1:93163431/C/T,1:93163436/T/
C,1:93163460/G/A,1:93167754/G/A,1:93201961/T/C 
HMGCR LDL 44985 3.47E-13 2 -0.184 0.026 SKAT,0.05 5:74646765/A/C,5:74652199/A/G 
 TC 46025 2.80E-10 2 -0.156 0.025 SKAT,0.05 5:74646765/A/C,5:74652199/A/G 
 54 
CD36 HDL 47456 5.17E-12 29 0.162 0.026 SKAT,0.01 7:80276061/G/T,7:80276070/G/T,7:80276111/C/A,7:
80285955/C/T,7:80286003/C/T,7:80286010/C/T,7:80
290384/G/A,7:80290467/C/A,7:80290477/C/T,7:8029
0500/T/C,7:80290507/T/C,7:80290509/C/T,7:802923
05/G/C,7:80292414/T/C,7:80292423/A/T,7:80292448
/C/T,7:80295802/A/G,7:80295807/T/C,7:80299280/T/
C,7:80300449/T/G,7:80301244/C/T,7:80301276/G/T,
7:80301310/T/G,7:80302093/G/T,7:80302102/T/G,7:
80302104/C/T,7:80302116/C/T,7:80302123/A/T,7:80
303453/C/T 
 
APOA1 HDL 47456 6.72E-10 2 -0.114 0.018 GRANVIL,0.05 11:116707044/A/T,11:116707736/C/T 
PCSK7 TG 43728 3.81E-7 12 0.053 0.012 SKAT,0.05 11:117076939/C/T,11:117076940/G/A,11:117077009/
A/C,11:117089205/C/T,11:117090309/G/A,11:11709
4001/T/G,11:117097932/G/A,11:117098967/C/T,11:1
17100134/C/A,11:117100257/C/T,11:117100340/G/A
,11:117100550/C/T 
CETP HDL 47456 1.60E-75 10 0.205 0.019 SKAT,0.05 16:56997025/T/G,16:57005908/C/A,16:57007387/C/T
,16:57012012/G/A,16:57012039/G/A,16:57012094/A/
G,16:57015076/G/A,16:57015091/G/C,16:57016086/
G/A,16:57017292/A/G 
 TC 46025 9.15E-13 10 0.042 0.019 SKAT,0.05 16:56997025/T/G,16:57005908/C/A,16:57007387/C/T
,16:57012012/G/A,16:57012039/G/A,16:57012094/A/
G,16:57015076/G/A,16:57015091/G/C,16:57016086/
G/A,16:57017292/A/G 
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LDLR LDL 44985 5.35E-11 16 0.502 0.074 VT,0.05 19:11213441/G/A,19:11213450/G/A,19:11213462/C/
T,19:11215926/G/A,19:11216275/C/A,19:11217303/
C/T,19:11217315/C/T,19:11218079/G/A,19:11221357
/G/A,19:11221411/G/A,19:11222300/G/A,19:112239
91/G/C,19:11230789/A/G,19:11231112/C/T,19:11233
940/G/A,19:11238731/G/A,19:11240240/G/A,19:112
41988/C/T 
 TC 46025 1.04E-7 16 0.411 0.073 VT,0.01 19:11213441/G/A,19:11213450/G/A,19:11213462/C/
T,19:11215926/G/A,19:11216275/C/A,19:11217303/
C/T,19:11217315/C/T,19:11218079/G/A,19:11221357
/G/A,19:11221411/G/A,19:11222300/G/A,19:112239
91/G/C,19:11230789/A/G,19:11231112/C/T,19:11233
940/G/A,19:11238731/G/A,19:11240240/G/A,19:112
41988/C/T 
PPARA TG 43728 2.27E-07 6 -0.088 0.018 SKAT,0.05 22:46611114/G/A,22:46615880/T/C,22:46627735/C/T
,22:46627780/C/T,22:46631108/A/T,22:46631206/A/
C 
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Supplementary Table 6. Association results for all significant coding variants at previously mapped GWAS loci 
GENE Position rsID Allele Variant ALT.FREQ Trait Effect P N 
PCSK9 1:55509585 rs151193009 T/C p.Arg93Cys 0.0132 LDL -0.542(0.029) 7.62E-77 44985 
     0.0134 TC -0.508(0.029) 3.96E-70 46025 
EVI5 1:93159927 rs117711462 A/G p.Arg354Cys 0.0069 TC 0.212(0.04) 1.41E-07 46025 
           0.0067 LDL 0.21(0.041) 3.23E-07 44985 
APOB 2:21225281 rs1042034 T/C p.Ser4338Asn 0.2651 TC -0.053(0.008) 3.40E-12 46025 
     0.2659 LDL -0.041(0.008) 9.75E-08 44985 
 2:21228437 rs376825639 G/A p.Ile3768Thr 0.0015 TC -0.659(0.097) 8.44E-12 36514 
     0.0015 LDL -0.579(0.098) 3.35E-09 34108 
 2:21231524 rs676210 A/G p.Pro2739Leu 0.7327 TC 0.049(0.008) 2.00E-09 38217 
 2:21252534 rs13306194 A/G p.Arg532Trp 0.1243 TG -0.073(0.01) 1.38E-12 43728 
     0.1239 TC -0.114(0.01) 1.45E-29 46025 
     0.1245 LDL -0.098(0.01) 9.53E-22 44985 
 2:21252807 noRS T/C p.Cys478Tyr 9.00E-04 LDL -0.772(0.141) 4.19E-08 28290 
     9.00E-04 TC -0.876(0.138) 2.08E-10 30697 
 2:21263900 rs1367117 A/G p.Thr98Ile 0.1296 TC 0.064(0.01) 8.96E-11 46025 
     0.1301 LDL 0.063(0.01) 4.26E-10 43617 
GTF3C2 2:27559188 rs76217877 C/G p.Ala411Gly 0.0526 TG -0.083(0.015) 5.68E-08 43728 
GCKR 2:27730940 rs1260326 C/T p.Leu446Pro 0.4957 TG -0.114(0.007) 1.26E-62 43728 
     0.4939 TC -0.047(0.007) 1.70E-12 46025 
C2orf16 2:27801759 rs1919128 G/A p.Ile774Val 0.4768 TG 0.077(0.007) 1.34E-29 43728 
     0.4773 TC 0.034(0.007) 2.97E-07 46025 
GPN1 2:27851918 rs3749147 A/G p.Arg12Lys 0.2935 TG 0.071(0.009) 7.87E-17 33583 
ANKRD31 5:74400516 rs56174528 C/G p.Thr1566Arg 0.1276 TC 0.059(0.01) 3.01E-09 46025 
     0.1277 LDL 0.065(0.01) 2.55E-10 43617 
 5:74442964 rs6893216 C/T p.Arg758Gly 0.152 LDL 0.056(0.01) 6.73E-08 35811 
 5:74443132 rs1422698 T/C p.Asp702Asn 0.4505 LDL 0.035(0.007) 2.23E-07 44985 
HMGCR 5:74646765 rs191835914 C/A p.Tyr311Ser 0.0174 TC -0.16(0.025) 2.00E-10 46025 
     0.0173 LDL -0.19(0.026) 2.20E-13 43617 
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MLXIPL 7:73012042 rs35332062 A/G p.Ala358Val 0.1094 TG -0.109(0.011) 2.03E-23 43728 
 7:73020337 rs3812316 G/C p.Gln241His 0.1001 TG -0.105(0.013) 2.16E-15 32630 
CD36 7:80302116 rs148910227 T/C p.Arg386Trp 0.0031 HDL 0.342(0.058) 3.17E-09 47456 
NAT2 8:18258103 rs1799930 A/G p.Arg197Gln 0.2535 TG -0.044(0.008) 1.30E-08 43728 
LPL 8:19819724 rs328 G/C p.Ser474* 0.0912 HDL 0.162(0.012) 7.55E-44 45989 
     0.0915 TG -0.169(0.012) 1.93E-45 43728 
ABCA1 9:107562804 rs2230808 C/T p.Lys1587Arg 0.6097 HDL 0.047(0.007) 2.49E-12 47456 
 9:107586753 rs2066714 C/T p.Ile883Met 0.7124 TC 0.041(0.007) 3.72E-08 46025 
     0.7123 HDL 0.052(0.007) 1.41E-12 47456 
ABO 9:136131651 rs1053878 A/G p.Pro156Leu 0.19 TC 0.065(0.009) 4.22E-14 46025 
     0.19 LDL 0.066(0.009) 5.07E-14 44985 
GPAM 10:113940329 rs2792751 C/T p.Ile43Val 0.7064 HDL -0.049(0.007) 7.14E-12 47456 
     0.7064 TC -0.043(0.007) 5.67E-09 46025 
BUD13 11:116633947 rs10488698 A/G p.Arg120Cys 0.082 HDL 0.095(0.012) 2.14E-15 47456 
     0.0818 TG -0.095(0.012) 2.59E-14 43728 
APOA5 11:116661392 rs2075291 A/C p.Gly185Cys 0.0556 TG 0.363(0.015) 1.12E-131 43728 
     0.0558 HDL -0.288(0.014) 3.91E-91 47456 
APOA4 11:116692334 rs5104 T/C p.Ser147Asn 0.6728 HDL 0.044(0.007) 2.79E-10 47456 
     0.6727 TG -0.121(0.007) 8.24E-61 43728 
APOA1 11:116707736 rs12718465 T/C p.Ala61Thr 0.0327 HDL -0.116(0.019) 5.50E-10 45989 
PAFAH1B2 11:117042377 rs4936367 A/G p.Val151Met 0.5048 TG -0.056(0.007) 5.60E-16 43728 
PCSK7 11:117100257 rs11542139 T/C p.Ala102Thr 0.045 TG 0.108(0.017) 9.85E-11 42556 
ACACB 12:109696838 rs2075260 A/G p.Val2141Ile 0.7434 TG 0.043(0.008) 3.95E-08 43728 
MMAB 12:109994870 rs9593 T/A p.Met239Lys 0.304 HDL 0.037(0.007) 2.92E-07 45989 
ALDH2 12:112241766 rs671 A/G p.Glu457Lys 0.2043 HDL -0.048(0.008) 1.16E-08 47456 
HNF1A 12:121416650 rs1169288 C/A p.Ile27Leu 0.4036 TC 0.038(0.007) 4.86E-08 43531 
CETP 16:56997025 rs201790757 G/T p.Tyr74* 3.00E-04 HDL 1.117(0.182) 8.97E-10 47456 
 16:57016092 rs5882 A/G p.Val362Ile 0.5426 HDL -0.055(0.007) 6.49E-17 47456 
 16:57017292 rs2303790 G/A p.Asp459Gly 0.0223 HDL 0.407(0.025) 7.53E-62 38181 
     0.0222 TC 0.145(0.025) 3.34E-09 38217 
SLC12A4 16:67997920 rs3785100 C/T p.Glu4Gly 0.1098 HDL 0.059(0.011) 5.13E-08 44817 
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PKD1L3 16:71967927 rs17358402 T/C p.Arg1572His 0.05411 TC 0.088(0.015) 1.96E-09 46025 
     0.05405 LDL 0.085(0.015) 2.11E-08 43617 
 16:72011181 rs1559401 T/G p.His571Gln 0.7374 LDL 0.058(0.008) 3.66E-14 44985 
     0.7386 TC 0.052(0.008) 4.54E-12 46025 
 16:72013797 rs7185272 C/G p.Thr429Ser 0.7392 LDL 0.059(0.008) 4.87E-14 43086 
     0.7398 TC 0.054(0.008) 1.65E-12 45494 
PMFBP1 16:72156842 rs16973716 G/T p.Lys768Asn 0.2896 TC 0.042(0.008) 1.75E-07 38217 
LIPG 18:47093864 rs2000813 T/C p.Thr111Ile 0.3106 HDL 0.043(0.007) 1.04E-09 47456 
LDLR 19:11217315 rs200990725 T/C p.Arg257Trp 9.00E-04 TC 0.677(0.109) 5.57E-10 46025 
     9.00E-04 LDL 0.882(0.109) 6.35E-16 44985 
SPC24 19:11257018 rs11557092 C/T p.Lys175Arg 0.7483 LDL 0.06(0.008) 9.65E-15 44985 
     0.7478 TC 0.051(0.008) 3.18E-11 46025 
TM6SF2 19:19379549 rs58542926 T/C p.Glu167Lys 0.0695 TG -0.094(0.013) 2.09E-12 43728 
     0.06918 TC -0.066(0.013) 4.25E-07 46025 
BCAM 19:45322744 rs1135062 G/A p.Thr539Ala 0.1091 LDL -0.056(0.011) 2.19E-07 44985 
APOE 19:45412079 rs7412 T/C p.Arg176Cys 0.0882 TC -0.281(0.016) 1.46E-71 25904 
     0.0882 TG 0.091(0.016) 7.32E-09 25722 
     0.0882 LDL -0.472(0.016) 4.87E-197 25730 
     0.0883 HDL 0.104(0.016) 3.95E-11 25746 
PPARA 22:46615880 rs1800234 C/T p.Val227Ala 0.0421 TG -0.094(0.018) 3.17E-07 35920 
ALT.FREQ, alternative allele frequency. 
Position is reported in human genome build hg19.  
Alleles are listed as alternative / reference allele on the forward strand of the reference genome.  
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Supplementary Table 7. Protein-altering variants are either the top signals, explain the signal or are independent of the 
original association signals   
  Index variants   Protein-altering variants 
r2 
Trait Locus rsID CHR_POS MAF P P.adjcoding   GENE rsID CHR_POS Variants MAF P P.adjindex 
Protein-altering variants are the top signals 
LDL PCSK9 rs2479409 1:55504650 32.66% 6.35E-01 3.12E-01  PCSK9 rs151193009 1:55509585 p.Arg93Cys 1.32% 7.62E-77 2.59E-75 0.006 
TC EVI5 rs7515577 1:93009438 4.31% 2.49E-02 3.23E-02  EVI5 rs117711462 1:93159927 p.Arg354Cys 0.69% 1.41E-07 2.35E-07 0.000 
HDL CD36 rs3211938 7:80300449 0.00% 8.69E-01 8.69E-01  CD36 rs148910227 7:80302116 p.Arg386Trp 0.31% 3.17E-09 3.60E-09 0.000 
HDL MVK rs7134594 12:110000193 30.33% 6.99E-07 7.32E-01  MMAB rs9593 12:109994870 p.Met239Lys 30.42% 2.92E-07 8.00E-01 0.993 
HDL BRAP rs11065987 12:112072424 0.3% 9.00E-01 9.83E-01  ALDH2 rs671 12:112241766 p.Glu457Lys 20.43% 1.16E-08 1.80E-08 0.001 
HDL LCAT rs16942887 16:67928042 3.01% 7.02E-02 3.00E-01  SLC12A4 rs3785100 16:67997920 p.Glu4Gly 10.98% 5.13E-08 3.01E-07 0.266 
LDL LDLR rs6511720 19:11202306 0.98% 4.19E-05 4.78E-05  LDLR rs200990725 19:11217315 p.Arg257Trp 0.09% 6.35E-16 8.05E-16 0.000 
TG PPARA rs4253772 22:46627603 0.18% 7.24E-01 7.01E-01  PPARA rs1800234 22:46615880 p.Val227Ala 4.21% 3.17E-07 3.16E-07 0.000 
TG GCKR rs1260326 2:27730940 49.57% 1.26E-62 1.00E+00  GCKR rs1260326 2:27730940 p.Leu446Pro 49.57% 1.26E-62 1.00E+00 1.000 
TG MLXIPL rs17145738 7:72982874 10.85% 7.05E-23 9.18E-01  MLXIPL rs35332062 7:73012042 p.Ala358Val 10.94% 2.03E-23 1.23E-01 0.977 
TC HNF1A rs1169288 12:121416650 40.36% 4.86E-08 1.00E+00  HNF1A rs1169288 12:121416650 p.Ile27Leu 40.36% 4.86E-08 1.00E+00 1.000 
TG TM6SF2 rs10401969 19:19407718 9.00% 3.15E-10 3.34E-01  TM6SF2 rs58542926 19:19379549 p.Glu167Lys 7.00% 2.09E-12 1.87E-03 0.677 
Protein-altering variants explain the original signals 
TG LPL rs12678919 8:19844222 9.07% 2.18E-45 1.94E-01  LPL rs328 8:19819724 p.Ser474* 9.15% 1.93E-45 2.13E-01 0.964 
LDL ABO rs635634 9:136155000 21% 3.11E-15 1.22E-02  ABO rs1053878 9:136131651 p.Pro156Leu 18.56% 5.07E-14 3.94E-01 0.801 
TC GPAM rs2255141 10:113933886 29.49% 5.33E-09 7.15E-01  GPAM rs2792751 10:113940329 p.Ile43Val 29.36% 5.67E-09 8.95E-01 0.990 
TC HPR rs2000999 16:72108093 25.88% 1.12E-08 2.54E-01  PMFBP1 rs16973716 16:72156842 p.Lys768Asn 28.96% 1.75E-07 6.59E-02 0.748 
Protein-altering variants are independent of original signals 
LDL APOB rs1367117 2:21263900 13.01% 4.26E-10 3.18E-07  APOB rs13306194 2:21252534 p.Arg532Trp 12.45% 9.53E-22 1.20E-18 0.016 
      1.20E-09  APOB rs376825639 2:21228437 p.Ile3768Thr 0.15% 3.35E-09 6.62E-09 0.001 
      9.44E-10  APOB noRS 2:21252807 p.Cys478Tyr 0.09% 4.19E-08 6.26E-08 0.000 
TC HMGCR rs3846663 5:74655726 52.48% 1.26E-23 9.79E-20  HMGCR rs191835914 5:74646765 p.Tyr311Ser 1.74% 2.00E-10 5.17E-07 0.018 
HDL ABCA1 rs1883025 9:107664301 22.84% 1.23E-23 1.03E-23  ABCA1 rs2230808 9:107562804 p.Lys1587Arg 39.03% 2.49E-12 8.09E-12 0.003 
      8.85E-21  ABCA1 rs2066714 9:107586753 p.Ile883Met 28.77% 1.41E-12 1.84E-09 0.014 
HDL APOA1 rs964184 11:116648917 22.00% 7.63E-39 4.63E-55  APOA5 rs2075291 11:116661392 p.Gly185Cys 5.56% 3.91E-91 1.97E-106 0.018 
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      8.61E-41  APOA1 rs12718465 11:116707736 p.Ala61Thr 3.27% 5.50E-10 8.95E-13 0.007 
TG MVK rs7134594 12:110000193 30.33% 6.69E-01 9.67E-01  ACACB rs2075260 12:109696838 p.Val2141Ile 25.66% 3.95E-08 7.48E-08 0.010 
HDL CETP rs3764261 16:56993324 16.45% 4.73E-152 1.02E-120  CETP rs2303790 16:57017292 p.Asp459Gly 2.23% 7.53E-62 3.37E-33 0.044 
      2.31E-149  CETP rs201790757 16:56997025 p.Tyr74* 0.03% 8.97E-10 1.42E-10 0.000 
TC HPR rs2000999 16:72108093 25.88% 1.12E-08 5.00E-06  PKD1L3 rs7185272 16:72013797 p.Thr429Ser 26% 1.65E-12 5.94E-10 0.031 
      1.33E-08  PKD1L3 rs17358402 16:71967927 p.Arg1572His 5.41% 1.96E-09 2.49E-09 0.002 
HDL LIPG rs7241918 18:47160953 11.73% 2.38E-04 7.95E-05  LIPG rs2000813 18:47093864 p.Thr111Ile 31.06% 1.04E-09 2.52E-10 0.008 
LDL APOE rs4420638 19:45422946 12.25% 3.27E-08 1.64E-04  APOE rs7412 19:45412079 p.Arg176Cys 8.82% 4.87E-197 3.46E-184 0.008 
Protein-altering is top: protein-altering variants are the most significant variants in the known loci. 
Explaining index: Conditional on the coding variants, the adjusted P for index variants (P.adj.coding) >0.01. 
Independent of index: Conditional on the index variants, the adjusted P for coding variants (P.adj.index) with significance (P < 4.5e-7) 
MAF, minor allele frequency 
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Supplementary Table 8. Genes previously identified to cause Mendelian dyslipidemia 
Genes Mendelian disorders of Lipids 
ABCA1 Tangier disease 
APOA1 ApoA-I deficiency hyperalphalipoproteinemia 
APOA5 ApoA-V deficiency hyperalphalipoproteinemia 
APOB Familial hypercholesterolemia 
APOE Familial  hyperlipoproteinemia 
CETP Cholesteryl ester transfer protein deficiency hyperalphalipoproteinemia 
LDLR Familial hypercholesterolemia 
LPL Lipoprotein lipase deficiency hypertriglyceridemia 
LIPG LIPG deficiency hyperalphalipoproteinemia 
PCSK9 Autosomal-dominant hypercholesterolemia 
 
 
 
 
 
 
 
 62 
Supplementary Table 9.  The association of the novel and potential functional lipid-associated variants with coronary artery 
disease in the CARDIoGRAM datasets and East Asian CAD data 
          CARDIOGRAMPlusC4D   East Asian CAD   
Loci Position rsID Allele Variant OR 95%CI ALT.FREQ P   OR 95%CI ALT.FREQ P N 
Novel variants 
ACVR1C 2:158437683 rs4377290 C/T  0.98(0.96-1) 0.453 1.84E-02  0.99(0.95-1.03) 0.315 7.14E-01 27373 
MCU 10:74637326 rs7901016 C/T  0.94(0.91-0.98) 0.094 4.55E-04  0.94(0.90-0.98) 0.274 2.80E-03 28899 
CD163 12:7649484 rs4883263 C/T p.Ile342Val 1.01(0.97-1.04) 0.905 5.98E-01  1.02(0.98-1.06) 0.687 3.87E-01 28899 
Known lipid loci 
LDL cholesterol            
PCSK9 1:55509585 rs151193009 T/C p.Arg93Cys     0.64(0.46-0.81) 0.014 7.19E-07 22365 
APOB 2:21252534 rs13306194 A/G p.Arg532Trp     0.9(0.84-0.96) 0.123 2.86E-04 28899 
APOB 2:21228437 rs376825639 G/A p.Ile3768Thr     0.19(-0.51-0.88) 0.001 2.06E-06 22365 
APOB 2:21252807 noRS T/C p.Cys478Tyr     0.32(-0.43-1.07) 0.001 2.92E-03 22365 
HMGCR 5:74646765 rs191835914 C/A p.Tyr311Ser     0.85(0.7-1) 0.02 3.76E-02 22365 
ABO 9:136131651 rs1053878 A/G p.Pro156Leu 1.02(0.98-1.05) 0.082 3.29E-01  1.07(1.02-1.13) 0.202 8.02E-03 23176 
PKD1L3 16:71967927 rs17358402 T/C p.Arg1572His 0.99(0.97-1.02) 0.232 6.46 E-01  1.05(0.97-1.13) 0.054 2.43E-01 28899 
PKD1L3 16:72013797 rs7185272 C/G p.Thr429Ser 1.01(0.99-1.03) 0.765 3.68 E-01  1.04(0.99-1.08) 0.75 1.45E-01 23176 
LDLR 19:11217315 rs200990725 T/C p.Arg257Trp     2.99(2.43-3.55) 0.001 1.41E-04 22365 
APOE 19:45412079 rs7412 T/C p.Arg176Cys 0.87(0.83-0.91) 0.074 8.17E-11  0.83(0.71-0.96) 0.084 4.77E-03 10731 
Total cholesterol            
EVI5 1:93159927 rs117711462 A/G p.Arg354Cys     1.15(0.9-1.4) 0.007 2.79E-01 22365 
HNF1A 12:121416650 rs1169288 C/A p.Ile27Leu 1.05(1.03-1.07) 0.347 1.98E-06  1.05(1.01-1.09) 0.42 1.71E-02 28899 
PMFBP1 16:72156842 rs16973716 G/T p.Lys768Asn 1.02(1-1.04) 0.436 6.67E-02  1.05(1.01-1.09) 0.287 1.47E-02 28899 
Triglycerides            
GCKR 2:27730940 rs1260326 C/T p.Leu446Pro 1(0.98-1.02) 0.61 7.35E-01  0.95(0.91-0.98) 0.476 3.42E-03 28899 
MLXIPL 7:73012042 rs35332062 A/G p.Ala358Val 1.01(0.98-1.04) 0.12 6.26E-01  0.99(0.93-1.05) 0.118 7.16E-01 28899 
LPL 8:19819724 rs328 G/C p.Ser474* 0.95(0.92-0.98) 0.096 1.81E-03  0.97(0.91-1.04) 0.087 4.04E-01 28899 
APOA5 11:116661392 rs2075291 A/C p.Gly185Cys     1.15(1.07-1.22) 0.061 5.95E-04 28899 
ACACB 12:109696838 rs2075260 A/G p.Val2141Ile 1.01(0.99-1.03) 0.769 4.53E-01  1.04(1-1.08) 0.731 4.60E-02 28899 
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TM6SF2 19:19379549 rs58542926 T/C p.Glu167Lys 0.95(0.91-0.99) 0.074 5.20E-03  0.94(0.86-1.02) 0.065 1.09E-01 28899 
PPARA 22:46615880 rs1800234 C/T p.Val227Ala     0.99(0.89-1.1) 0.054 9.18E-01 21650 
HDL cholesterol            
CD36 7:80302116 rs148910227 T/C p.Arg386Trp     0.71(0.35-1.06) 0.004 5.34E-02 22365 
ABCA1 9:107562804 rs2230808 C/T p.Lys1587Arg 1.02(1-1.04) 0.71 1.12E-01  0.98(0.94-1.02) 0.624 3.76E-01 28899 
ABCA1 9:107586753 rs2066714 C/T p.Ile883Met 1.05(1.02-1.07) 0.166 3.22 E-04  1.04(1-1.08) 0.727 6.53E-02 28899 
GPAM 10:113940329 rs2792751 C/T p.Ile43Val 0.99(0.97-1.01) 0.712 3.01E-01  0.98(0.94-1.02) 0.682 4.15E-01 28899 
APOA1 11:116707736 rs12718465 T/C p.Ala61Thr     1.08(0.97-1.19) 0.032 1.83E-01 28899 
MMAB 12:109994870 rs9593 T/A p.Met239Lys 1.01(0.99-1.02) 0.511 5.83E-01  1.01(0.97-1.05) 0.301 5.40E-01 28899 
ALDH2 12:112241766 rs671 A/G p.Glu457Lys     1.08(1.03-1.12) 0.203 2.07E-03 28899 
CETP 16:56997025 rs201790757 G/T p.Tyr74*     0.47(-0.65-1.59) 0 1.89E-01 22365 
CETP 16:57017292 rs2303790 G/A p.Asp459Gly     0.99(0.86-1.12) 0.025 9.20E-01 27373 
SLC12A4 16:67997920 rs3785100 C/T p.Glu4Gly 1.01(0.99-1.04) 0.145 3.26E-01  1.03(0.97-1.09) 0.115 3.87E-01 28899 
LIPG 18:47093864 rs2000813 T/C p.Thr111Ile 0.97(0.95-0.99) 0.289 9.11E-03  1.02(0.98-1.06) 0.293 4.43E-01 28899 
ALT.FREQ, alternative allele frequency. 
Position is reported in human genome build hg19.  
Alleles are listed as alternative / reference allele on the forward strand of the reference genome.  
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Supplementary Table 10. Association results of the novel variants in combined current studies, HUNT, GLGC GWAS, and 
Chinese GWAS samples 
    
East Asian and GLGC exome 
 
HUNT 
 
GLGC GWAS  Chinese GWAS  Combined Samples 
Gene rsID Allele Trait EAF N P   N P   N P  N P  N BETA(S.E.) P 
ACVR1C rs4377290 C/T TC 0.44 358251 6.06E-08 
 
61924 0.005  
 
48567 0.064   13648 0.014   482390 -0.014(0.002) 5.583E-11 
MCU rs7901016 C/T LDL 0.12 298452 2.21E-09 
 
61898 0.370  
 
44290 0.178   14028 1.28E-03  418668 -0.027(0.004) 3.004E-11 
CD163 rs4883263 C/T HDL 0.9 356397 6.30E-13 
 
61907 0.120  
 
48286 0.756   14137 5.91E-04  480727 -0.031(0.004) 2.134E-14 
PDGFC rs4691380 T/C HDL 0.35 335481 1.07E-07 
 
61907 0.0004 
 
48426 3.84E-04  13936 0.727   459750 0.016(0.002) 4.919E-12 
FAM114A2 rs2578377 T/C HDL 0.67 335481 1.74E-07 
 
61907 0.520  
 
48428 0.035   14141 0.166   459957 -0.013(0.002) 2.194E-08 
MGAT1 rs634501 G/A HDL 0.72 337027 9.36E-08 
 
61907 0.004  
 
2992 0.084   12365 0.899   414291 -0.015(0.002) 4.451E-09 
ASCC3 rs9390698 A/G TC 0.39 358251 5.22E-09 
 
61924 0.0002 
 
45531 0.015   14150 0.210   479856 0.016(0.002) 1.056E-13 
   
LDL 0.39 331991 5.84E-08 
 
61898 0.0006 
 
41339 0.008   14063 0.026   449291 0.016(0.002) 1.317E-12 
LOC100996634 rs884366 A/G HDL 0.31 327673 1.45E-08 
 
61907 0.003  
 
88652 8.50E-05  14148 0.083   492380 -0.017(0.002) 8.678E-14 
EEPD1 rs4302748 A/G LDL 0.18 333359 2.10E-08 
 
61898 0.012  
 
44285 0.721   13991 0.577   453533 0.016(0.003) 4.69E-09 
PLCE1 rs2274224 C/G TC 0.44 150798 9.92E-08 
 
61924 0.0006 
 
89016 0.132   9329 0.094   311067 -0.017(0.003) 6.752E-10 
EIF4B rs7306523 G/A TC 0.71 338266 5.36E-08 
 
61924 0.180  
 
48567 0.671   14150 0.505   462907 -0.015(0.003) 4.309E-08 
   
LDL 0.71 313750 1.38E-07 
 
61898 0.210  
 
44290 0.454   14063 0.129   434001 -0.016(0.003) 2.654E-08 
SLC17A8 rs7965082 T/C TC 0.52 358251 8.28E-09 
 
61924 0.013  
 
48567 8.58E-04  14151 0.106   482893 -0.015(0.002) 7.577E-13 
   
LDL 0.52 333359 9.21E-08   61898 0.009    44290 0.025   14064 0.082   453611 -0.014(0.002) 4.939E-11 
We performed in silico replication of significant variants in the HUNT-MI study (Health in Nord-Trøndelag and University of Michigan) (max n= 62,168) (Int J Epidemiol. 2013;42:968-77), GLGC 
GWAS samples (max n=89,016)  (being careful to exclude the samples overlapping GLGC exome samples) (Nat Genet. 2013;45:1274-83), and Chinese subjects from Chinese lipids GWAS (max n= 
14,151) (Circ Cardiovasc Genet 2016;9:37-44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
Supplementary Table 12. Expression quantitative trait locus (eQTL)of novel variants and proxies (P < 4.5e-7) 
Gene rsID chr.pos 
Lead 
/proxy 
r
2
 with lead SNP Gencode Id Effect Size P Tissue 
FAM114A2 rs34077744 5:153376314 proxy 0.99(rs2578377) ENSG00000055147.13 0.16  3.64E-07 Whole_Blood 
ASCC3 rs9390698 6:101296389 lead  ENSG00000112249.9 -0.23  2.35E-08 Artery_Tibial 
LOC100996634 rs884366 6:109574095 lead  ENSG00000203799.6 -0.53  1.38E-16 Whole_Blood 
EEPD1 rs11771125 7:36190426 proxy 0.95(rs4302748) ENSG00000122547.6 -0.26  3.79E-07 Whole_Blood 
PLCE1 rs2274224 10:96039597 lead  ENSG00000173145.7 0.53 5.78E-10 Adrenal_Gland 
For each of the newly discovered loci, all proxies (r
2
 > 0.8) were identified using data from 1000 genome East Asian. Cis-eQTL (defined as genes 
within 1 Mb) of lead variants and their proxies were investigated in public databases including the following tissues and cell lines: liver, artery, 
LCL, adipose, heart, blood and adrenal gland.  
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Supplementary Table 13. The association of the potential functional lipid-associated variants identified in East Asian with 
lipid levels in GLGC 
            East Asian   GLGC 
Loci Position rsID Allele Variant Trait ALT.FREQ Effect P   ALT.FREQ Effect P 
Low-frequency and rare coding variants in East Asian are not significant in GLGC      
EVI5 1:93159927 rs117711462 A/G p.Arg354Cys TC 0.69% 0.212(0.04) 1.41E-07  0.03% 0.097(0.083) 0.245 
     LDL 0.67% 0.21(0.041) 3.23E-07  0.03% 0.078(0.085) 0.3608 
APOB 2:21228437 rs376825639 G/A p.Ile3768Thr TC 0.15% -0.659(0.097) 8.44E-12     
     LDL 0.15% -0.579(0.098) 3.35E-09     
APOB 2:21252807 noRS T/C p.Cys478Tyr LDL 0.09% -0.772(0.141) 4.19E-08     
     TC 0.09% -0.876(0.138) 2.08E-10     
HMGCR 5:74646765 rs191835914 C/A p.Tyr311Ser TC 1.74% -0.16(0.025) 2.00E-10  0.04% -0.102(0.064) 0.1087 
     LDL 1.73% -0.19(0.026) 2.20E-13  0.04% -0.117(0.067) 0.07949 
CD36 7:80302116 rs148910227 T/C p.Arg386Trp HDL 0.31% 0.342(0.058) 3.17E-09  0.02% 0.215(0.084) 0.01045 
APOA1 11:116707736 rs12718465 T/C p.Ala61Thr HDL 3.27% -0.116(0.019) 5.50E-10  0.02% 0.075(0.099) 0.4487 
CETP 16:56997025 rs201790757 G/T p.Tyr74* HDL 0.03% 1.117(0.182) 8.97E-10  0.001% 0.719(0.352) 0.04113 
CETP 16:57017292 rs2303790 G/A p.Asp459Gly HDL 2.23% 0.407(0.025) 7.53E-62  0.02% 0.384(0.092) 3.16E-05 
     TC 2.22% 0.145(0.025) 3.34E-09  0.02% 0.065(0.092) 0.4828 
LDLR 19:11217315 rs200990725 T/C p.Arg257Trp TC 0.09% 0.677(0.109) 5.57E-10  0.001% 1.897(0.502) 1.57E-04 
     LDL 0.09% 0.882(0.109) 6.35E-16  0.001% 1.869(0.502) 1.96E-04 
PPARA 22:46615880 rs1800234 C/T p.Val227Ala TG 4.21% -0.094(0.018) 3.17E-07  0.15% -0.058(0.037) 0.1179 
Low-frequency and rare coding variants in East Asian are significant in GLGC      
PCSK9 1:55509585 rs151193009 T/C p.Arg93Cys TC 1.34% -0.508(0.029) 3.96E-70  0.01% -0.71(0.133) 1.03E-07 
     LDL 1.32% -0.542(0.029) 7.62E-77  0.01% -0.801(0.139) 7.62E-09 
Common coding variants in East Asian are not significant in GLGC      
APOB 2:21252534 rs13306194 A/G p.Arg532Trp TC 12.39% -0.114(0.01) 1.45E-29  0.19% -0.084(0.031) 0.006743 
     LDL 12.45% -0.098(0.01) 9.53E-22  0.20% -0.085(0.032) 0.008126 
     TG 12.43% -0.073(0.01) 1.38E-12  0.19% -0.133(0.032) 2.96E-05 
ABO 9:136131651 rs1053878 A/G p.Pro156Leu LDL 18.56% 0.066(0.009) 5.07E-14  8.06% 0.016(0.005) 0.001346 
ACACB 12:109696838 rs2075260 A/G p.Val2141Ile TG 74.34% 0.043(0.008) 3.95E-08  80.23% 0.011(0.003) 5.32E-04 
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ALDH2 12:112241766 rs671 A/G p.Glu457Lys HDL 20.43% -0.048(0.008) 1.16E-08  0.08% -0.005(0.052) 0.928 
PKD1L3 16:71967927 rs17358402 T/C p.Arg1572His TC 5.41% 0.088(0.015) 1.96E-09  24.44% -0.009(0.003) 0.003724 
     LDL 5.41% 0.085(0.015) 2.11E-08  24.44% -0.013(0.003) 8.47E-05 
PMFBP1 16:72156842 rs16973716 G/T p.Lys768Asn TC 28.96% 0.042(0.008) 1.75E-07  44.69% 0.014(0.003) 2.66E-07 
Common functional coding variants in East Asian are significant in GLGC      
GCKR 2:27730940 rs1260326 C/T p.Leu446Pro TC 49.39% -0.047(0.007) 1.70E-12  63.19% -0.058(0.003) 5.84E-101 
     TG 49.57% -0.114(0.007) 1.26E-62  63.23% -0.121(0.003) 0 
MLXIPL 7:73012042 rs35332062 A/G p.Ala358Val TG 10.94% -0.109(0.011) 2.03E-23  11.61% -0.123(0.004) 6.40E-188 
LPL 8:19819724 rs328 G/C p.Ser474NA HDL 9.12% 0.162(0.012) 7.55E-44  9.83% 0.163(0.004) 1.18E-306 
     TG 9.15% -0.169(0.012) 1.93E-45  9.84% -0.183(0.004) 0 
ABCA1 9:107562804 rs2230808 C/T p.Lys1587Arg HDL 60.97% 0.047(0.007) 2.49E-12  72.96% 0.027(0.003) 9.78E-19 
ABCA1 9:107586753 rs2066714 C/T p.Ile883Met TC 71.24% 0.041(0.007) 3.72E-08  15.11% 0.032(0.004) 6.95E-18 
     HDL 71.23% 0.052(0.007) 1.41E-12  15.13% 0.043(0.004) 2.03E-30 
GPAM 10:113940329 rs2792751 C/T p.Ile43Val TC 70.64% -0.043(0.007) 5.67E-09  72.98% -0.028(0.003) 1.62E-21 
     HDL 70.64% -0.049(0.007) 7.14E-12  72.99% -0.027(0.003) 3.90E-20 
APOA5 11:116661392 rs2075291 A/C p.Gly185Cys TG 5.56% 0.363(0.015) 1.12E-131  0.16% 0.37(0.033) 1.94E-29 
     HDL 5.58% -0.288(0.014) 3.91E-91  0.16% -0.262(0.033) 1.20E-15 
MMAB 12:109994870 rs9593 T/A p.Met239Lys HDL 30.42% 0.037(0.007) 2.92E-07  53.14% 0.03(0.003) 9.15E-29 
HNF1A 12:121416650 rs1169288 C/A p.Ile27Leu TC 40.36% 0.038(0.007) 4.86E-08  33.01% 0.037(0.003) 5.88E-38 
SLC12A4 16:67997920 rs3785100 C/T p.Glu4Gly HDL 10.98% 0.059(0.011) 5.13E-08  14.09% 0.072(0.004) 7.57E-67 
PKD1L3 16:72013797 rs7185272 C/G p.Thr429Ser TC 73.98% 0.054(0.008) 1.65E-12  78.69% 0.021(0.003) 6.11E-11 
     LDL 73.92% 0.059(0.008) 4.87E-14  78.68% 0.021(0.003) 7.44E-11 
LIPG 18:47093864 rs2000813 T/C p.Thr111Ile HDL 31.06% 0.043(0.007) 1.04E-09  28.61% 0.039(0.003) 1.76E-41 
TM6SF2 19:19379549 rs58542926 T/C p.Glu167Lys TC 6.92% -0.066(0.013) 4.25E-07  7.44% -0.131(0.005) 5.71E-156 
     TG 6.95% -0.094(0.013) 2.09E-12  7.46% -0.119(0.005) 1.20E-123 
APOE 19:45412079 rs7412 T/C p.Arg176Cys TG 8.82% 0.091(0.016) 7.32E-09  7.42% 0.124(0.007) 2.54E-79 
     HDL 8.83% 0.104(0.016) 3.95E-11  7.42% 0.098(0.006) 2.63E-52 
     LDL 8.82% -0.472(0.016) 4.87E-197   7.38% -0.535(0.007) 0 
ALT.FREQ, alternative allele frequency. 
Position is reported in human genome build hg19.  
Alleles are listed as alternative / reference allele on the forward strand of the reference genome.  
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 Supplementary Figures 
Supplementary Figure 1. Genezoom plots for the 9 genes that reached gene-based significance (P< 2.8 × 10
-6
) with blood lipid 
levels 
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Supplementary Figure 2. Relationship between the effect sizes on CAD and lipid levels for the novel and potential function 
variants identified in East Asian population 
All lipid and CAD effect sizes estimated by the Chinese samples were oriented to the alternate allele (hg19). Lipid effect sizes were 
transformed into SD units. Circles represent 31 potential function variants while triangles denote novel variants. 
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Supplementary Figure 3. Forest plots for the novel variants. 
GLGC samples(AA: African American; EUR: European; HS: Spanish; SAS: South Asian); EAS: East Asian 
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Supplementary Figure 4. Heatmaps of  deltaSVM scores used to predict the impact of regulatory variants in noncoding regions  
DeltaSVM uses a gapped k-mer support vector machine to estimate the effect of a variant in a cell-type-specific manner (Nat Genet. 2015 
47(8):955-61). Precomputed weights were available from a total of 222 ENCODE DHS samples—99 from the Duke University (Duke) set and 
123 from the University of Washington (UW) set (Nature. 2012;489(7414):75-82). For the current study, genetic variants were scored for 
deltaSVM in 81 cell lines from four tissues (blood, blood vessel, heart and liver). For each of the seven novel noncoding regions, all proxies (r
2
 > 
0.8) were identified using data from 1000 genome.  The deltaSVM scores are represented as different color gradients, and the variants with 
deltaSVM score greater than an absolute value of 5 are highlighted with asterisk. The regulatory deltaSVM score of 5 is in  the same range as 
previous predictions for known functional SNPs (Nat Genet. 2015 47(8):955-61). 
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Supplementary Figure 5. Comparison of effect sizes and frequency between East Asian and GLGC for 31 functional coding 
variants identified in East Asian population 
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Supplementary Figure 6. Comparison of effect sizes and frequencies between East Asian and GLGC for coding variants 
identified in GLGC.  
Among 156 independent coding variants in the known loci in GLGC samples (Supplementary table 11), 77 are low-frequency and rare 
coding variants (MAF < 0.05), and 60 (77.9%) show at least 10 fold lower frequency or are monomorphic in East Asian samples. 
Among 19 low-frequency and rare putative functional variants identified in GLGC samples (Supplementary Table 11), 17 (89.5%) 
were extremely rare or monomorphic in East Asian samples. 
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Supplementary Figure 7. Comparison of effect sizes of GWAS index and the corresponding potential functional variants 
across ethnic groups  
Among 25 loci harboring both GWAS index and the corresponding potential functional variants, the GWAS index variants in 9 loci 
do not reached significant in East Asians. For the GWAS index variants that could not be replicated in East Asian samples, effect sizes 
are not related (r
2
 = 0.02, P = 0.71) between East Asian and Europeans, while the effect sizes of the corresponding coding variants are 
strongly related (r
2
 = 0.91, P = 2.2 ×10
-5
). We also observed that the effect sizes of coding variants were larger than those of index 
variants, even for the loci where the initial GWAS index variants showed significance in East Asian samples. 
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Supplementary Figure 8. Quantile-quantile plots of association P-values for TG, HDL-C, LDL-C and TC. 
Red points represent the p-value distribution of the variants in the 175 known loci (±1Mb) while blue points denote the distribution after removal 
of variants mapping to the known loci. 
 
 
 
 
 
 
 
